Contact

Merck KGaA, Darmstadt, Germany Investor Relations Frankfurter Strasse 250 64293 Darmstadt Germany

Phone: +49 6151 72 3321

e-mail: investor.relations@emdgroup.com

www.emdgroup.com

WKN: 659990

ISIN: DE0006599905

Ticker Symbol: MRK

Financial Statements Q1 2023 - Q4 2024

Content

1 Income statements

- 1.1 Group, quarterly
- 1.2 Life Science, quarterly
- 1.3 Healthcare, quarterly
- 1.4 Electronics, quarterly
- 1.5 Corporate/Others, quarterly
- 1.6 Financial result, quarterly

2 Cash flow statement

3 Balance sheet

Net sales/Net sales grow	wth by business secto	r Merck KO	aA, Darms		any											_	_															
€ million	Q1	Q2	H1	2023 Q3	9M	Q4	H2	FY	Q1	Q2	H1	2024 Q3	9M	Q4	H2	FΥ		Q1	Q2	H1	2023 Q3	9M	Q4	H2	FY	Q1	Q2	H1	202 4 Q3	4 9M	Q4	H2 FY
Group	5,293.0	5,302.4	10,595.3	5,173.1	15,768.4	5,224.5	10,397.6	20,992.9	5,119.8	5,352.2	10,472.0	5,266.1	15,738.0	5,417.7	10,683.8 21,1	5.8 Group																
YoY Δ	95.2		-170.8	-632.7	-803.5	-435.9	-1,068.5	-1,239.3	-173.2	49.8	-123.4	93.0	-30.4	193.2		2.8 YoY %		1.8%	-4.8%				-7.7%		-5.6%	-3.3%		-1.2%				2.8% 0.8%
Acquisitions ∆	9.4		12.6	3.1	15.6	3.4	6.4	19.0	-0.6	-2.2	-2.7	-1.9	-4.6	20.0			sitions %	0.2%	0.1%		0.1%	0.1%	0.1%	0.1%	0.1%	0.0%	0.0%	0.0%	0.0%	0.0%		0.1%
FxΔ	43.5		-163.9	-395.5	-559.4	-342.4	-737.9 -337.1	-901.8	-108.3	-38.4	-146.7	-102.6	-249.3	-27.6		7.0 Fx % 1.5 Organ	. 0/	0.8%	-3.7%					-6.4%		-2.0%						.3% -1.3%
Organic ∆ Life Science	42.3	-61.8 2,353.5	-19.5 4.840.3	-240.2 2.190.9	-259.7 7.031.2	-96.9 2.249.4	4.440.2	-356.6 9.280.5	-64.3 2.143.7	90.4 2,258.1	26.1 4.401.8	197.5 2,209.7	223.6	200.9 2.304.5	398.4 4 4,514.2 8,9			0.8%	-1.1%	-0.2%	-4.1%	-1.6%	-1.7%	-2.9%	-1.6%	-1.2%	1.7%	0.2%	3.8%	1.4%	3.8% 3	3.8% 2.0%
YoY A	41.4		-252.9	-489.9	-742.7	-357.1	-846.9	-1.099.8	-343.1	-95.5	-438.5	18.8	-419.7	55.2	74.0 -3		lice	1.7%	-11.1%	-5.0%	18 3%	-0.6%	-13 7%	-16.0%	-10.6%	-13.8%	-4.1%	-9.1%	0.9%	-6.0%	2.5% 1	.7% -3.9%
Acquisitions ∆	6.3		6.0	0.1	6.2	0.1	0.2	6.3	0.0	0.0	0.0	0.0	0.0	6.7	6.7		sitions %	0.3%	0.0%	0.1%	0.0%	0.1%	0.0%	0.0%	0.1%	0.0%	0.0%	0.0%	0.0%	0.0%		0.1%
FxΔ	20.9		-43.7	-135.7	-179.4	-105.3	-240.9	-284.6	-30.4	-8.5	-38.9	-27.2	-66.1	4.8	-22.5 -	I.3 Fx %		0.9%	-2.4%	-0.9%	-5.1%	-2.3%	-4.0%			-1.2%			-1.2%	-0.9%		0.5% -0.7%
Organic Δ	14.2		-215.2	-354.3	-569.6	-251.9	-606.2	-821.5	-312.7	-87.0	-399.7	46.1	-353.6	43.7	89.8 -3		ic %	0.6%		-4.2%												2.0% -3.3%
Healthcare	1,905.5			2,066.3	6,021.3	2,031.9	4,098.2	8,053.2	2,047.7	2,136.7	4,184.4	2,133.4		2,136.7	4,270.1 8,4		re															
YoY A	110.5		235.9	-23.0	212.8	1.6	-21.4	214.5	142.2	87.2	229.4	67.1	296.5	104.8		1.3 YoY %		6.2%	6.5%		-1.1%	3.7%			2.7%	7.5%	4.3%	5.8%	3.2%			.2% 5.0%
Acquisitions ∆	0.0		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0			sitions %	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%		0.0%
FxΔ	14.8			-178.1	-267.9	-185.7	-363.8	-453.6	-49.3	-21.8	-71.2	-62.0	-133.2	-31.1		1.3 Fx %		0.8%	-5.4%			-4.6%	-9.1%		-5.8%				-3.0%			2.3% -2.0%
Organic Δ Electronics	95.7 900.7		325.7 1.800.0	155.1 915.9	480.8 2.715.9	187.3	342.4 1.859.1	668.1 3.659.2	191.5 928.4	109.1	300.6 1.885.8	129.1	429.7 2.808.8	135.9	265.0 5			5.3%	11.9%	8.8%	7.4%	8.3%	9.2%	8.3%	8.5%	10.1%	5.3%	7.6%	6.2%	7.1%	6.7% 6	7.0%
YoY A	-56.7	-97.1	-153.8	-119.8	-273.6	943.2 -80.4	-200.2	-354.0	27.7	957.4 58.1	85.8	923.0 7.1	92.8	976.5 33.3	1,899.5 3,7 40.3 1	5.1 YoY %	cs	-5.9%	-9.7%	-7.9%	-11.6%	-9.2%	-7.9%	-9.7%	-8.8%	3.1%	6.5%	4.8%	0.8%	3.4%	3.5% 2	2.2% 3.4%
Acquisitions ∆	-56.7		6.5	2.9	9.5	3.3	6.2	12.8	-0.6	-2.2	-2.7	-1.9	-4.6	13.3	11.4		sitions %	0.3%	0.3%	0.3%	0.3%	0.3%	0.3%	0.3%	0.3%	-0.1%			-0.2%			1.2% 3.4% 1.6% 0.2%
Fx A	7.7			-81.7	-112.1	-51.4	-133.2	-163.6	-28.6	-8.1	-36.7	-13.4	-50.1	-1.3		1.3 Fx %	3100113 70	0.8%	-3.8%	-1.6%				-6.5%								0.8% -1.4%
Organic Δ	-67.6			-41.0	-170.9	-32.3	-73.3	-203.2	56.8	68.3	125.2	22.3	147.5	21.3		3.8 Organ	ic %	-7.1%														2.3% 4.6%
€ million	Q1			Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	· ·	€ million		Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2 FY
Group % Margin	1,587.0	1,553.3 29.3%	3,140.3 29.6%	1,445.6 27.9%	4,585.9 29.1%	1,293.0 24.7%	2,738.7 26.3%	5,878.9 28.0%	1,453.9 28.4%	1,508.9 28.2%	2,962.8 28.3%	1,617.7 30.7%	4,580.6 29.1%	1,491.1 27.5%	3,108.8 6,0 29.1% 28																	
% wargin YoY∆	30.0% -41.8		-270.5	-364.8	-635.3	-334.9	-699.7	-970.2	-133.1	-44.3	-177.4	172.1	-5.4	198.0		2.7 YoY %		-2.6%	-12.8%	-7 Q% ·	-20.2%	-12 2%	-20.6%	-20.3%	-1/1 2%	-8.4%	-2.9%	-5.7%	11.9%	-0.1%	15.3% 13	55% 3.3%
Acquisitions ∆	-6.1	-3.0	-9.1	-5.7	-14.9	-5.0	-10.7	-19.9	0.0	-0.1	-0.1	-0.2	-0.3	-2.8			sitions %	-0.4%	-0.2%				-0.3%		-0.3%	0.0%	0.0%	0.0%	0.0%			1.5% -0.1%
FxΔ	-7.7			-120.1	-229.0	-106.4	-226.5	-335.4	-50.7	-32.0	-82.8	-71.8	-154.6	-54.3		3.9 Fx %		-0.5%	-5.7%	-3.2%				-6.6%		-3.2%						-3.6%
Organic Δ	-27.9		-152.5	-239.0	-391.5	-223.5	-462.5	-615.0	-82.4	-12.2	-94.6	244.1	149.5	255.1	499.2 4			-1.7%	-7.0%	-4.5% -	-13.2%	-7.5%	-13.7%	-13.5%	-9.0%	-5.2%	-0.8%	-3.0%	16.9%	3.3%	19.7% 18	8.2% 6.9%
Life Science	900.6			615.1	2,227.6	592.0	1,207.1	2,819.6	611.2	654.7	1,265.9		1,912.4	676.8	1,323.3 2,5		nce															
% Margin	36.2%		33.3%	28.1%	31.7%	26.3%	27.2%	30.4%	28.5%	29.0%	28.8%	29.3%	28.9%	29.4%	29.3% 29																	
YoY ∆ Acquisitions ∆	-26.5 -4.3		-320.3 -2.7	-361.3 -7.0	-681.6 -9.8	-258.3 -1.4	-619.6 -8.5	-939.9 -11.2	-289.4 0.0	-57.2 0.0	-346.6 0.0	31.3 0.0	-315.3 0.0	84.8 -5.2		0.5 YoY % 5.2 Acquis	sitions %	-2.9% -0.5%	-29.2% 0.2%				-30.4%	-33.9%	-25.0%	-32.1% 0.0%	-8.0% 0.0%	-21.5% 0.0%	5.1%			0.6% -8.2% 0.4% -0.2%
Fx A	-9.4		-42.2	-46.6	-88.8	-35.6	-82.3	-124.4	-16.6	-13.6	-30.2	-12.1	-42.4	-4.8		7.1 Fx %	SIUOTIS 70	-1.0%		-2.2%				-4.5%								.4% -1.7%
Organic Δ	-12.8		-275.4	-307.6	-583.0	-221.3	-528.9	-804.3	-272.8	-43.6	-316.4	43.4	-272.9	94.8	138.2 -1		ic %	-1.4%		-14.2%												.4% -6.3%
Healthcare	589.6		1,293.2	685.4	1,978.5	564.5	1,249.9	2,543.1	708.0	719.8	1,427.8	835.7	2,263.5	731.2	1,566.9 2,9																	
% Margin	30.9%	34.3%	32.7%	33.2%	32.9%	27.8%	30.5%	31.6%	34.6%	33.7%	34.1%	39.2%	35.8%	34.2%	36.7% 35	1%																
YoY Δ	60.5			-25.5	135.0	-68.5	-94.0	66.5	118.4	16.2	134.6	150.3	284.9	166.7		I.6 YoY %		11.4%	16.6%		-3.6%	7.3%		-7.0%		20.1%		10.4%				5.4% 17.8%
Acquisitions ∆	0.0	0.0	0.0	0.0	0.0	0.0 -129.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0			sitions %	0.0%	0.0%		0.0%		0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%			0.0%
							-277.0	-355.8	-48.6	-16.4	-65.0 199.6	-34.8 185.1	-99.8 384.7	-26.4 193.0		6.1 Fx %	:- 0/	0.9% 10.5%		-7.0% -								-5.0%				1.9% -5.0% 1.3% 22.7%
FxΔ	4.9			-148.0	-226.8			400.0				185.1	384./			7.7 Organ	IC %	10.5%	3∪.4%	21.1%	17.2%	19.6%	9.6%	1.5 6%								
Fx Δ Organic Δ	4.9 55.6	183.8	239.3	122.5	361.8	60.5	183.0	422.3	167.0	32.6		235.2	727 1	242 5	477 7 Q	6 Floctroni	ce									20.070	4.0 /0	10.470	27.0%	19.4%	04.2% JU	.070 EE.170
Fx Δ Organic Δ Electronics	4.9 55.6 237.3	183.8 261.7	239.3 499.1	122.5 207.9	361.8 707.0	60.5 206.0	183.0 413.9	913.0	236.6	255.3	491.9	235.2 25.5%	727.1 25.9%	242.5 24.8%		9.6 Electroni	cs									20.070	4.076	10.470	27.0%	19.4%	54.2% SU	LE.I II
Fx Δ Organic Δ	4.9 55.6 237.3 26.4%	183.8 261.7 29.1%	239.3	122.5 207.9 22.7%	361.8	60.5 206.0 21.8%	183.0 413.9 22.3%	913.0 25.0%		255.3 26.7%	491.9 26.1%	235.2 25.5% 27.4	25.9%	24.8%	25.2% 25	5%	cs	-18.0%	-10.7%	-14.3%	-31.1%	-20.0%	-33.1%			-0.3%			13.2%			5.4% 6.2%
Fx Δ Organic Δ Electronics % Margin	4.9 55.6 237.3	183.8 261.7 29.1% -31.3	239.3 499.1 27.7%	122.5 207.9	361.8 707.0 26.0%	60.5 206.0	183.0 413.9	913.0	236.6 25.5%	255.3	491.9	25.5%			25.2% 25	6% 6.6 YoY %	ics sitions %	-18.0% -0.4%	-10.7% -0.5%		-31.1% -0.7%		-33.1% -1.1%	-32.1%				-1.4%		2.9%	17.7% 15	
Fx Δ Organic Δ Electronics % Margin YoY Δ	4.9 55.6 237.3 26.4% -52.0 -1.3 6.6	183.8 261.7 29.1% -31.3 -1.6 -14.5	239.3 499.1 27.7% -83.3 -2.9 -7.9	122.5 207.9 22.7% -93.7 -2.1 -37.9	361.8 707.0 26.0% -177.1	60.5 206.0 21.8% -102.2 -3.2 -20.9	183.0 413.9 22.3% -195.9 -5.4 -58.8	913.0 25.0% -279.2 -8.3 -66.7	236.6 25.5% -0.7 0.0 -10.0	255.3 26.7% -6.5 -0.1 1.7	491.9 26.1% -7.2 -0.1 -8.3	25.5% 27.4	25.9% 20.2 -0.3 -11.9	24.8% 36.5 2.5 3.1	25.2% 25 63.8 2.4 -0.5	6% 6.6 YoY % 2.3 Acquis 3.8 Fx %			-0.5%		-0.7%	-0.6%	-1.1%	-32.1% -0.9%	-23.4% -0.7%	-0.3%	-2.5% 0.0%	-1.4% 0.0%	13.2%	2.9% 0.0%	17.7% 15 1.2% 0	i.4% 6.2%
	4.9 55.6 237.3 26.4% -52.0 -1.3 6.6 -57.3	183.8 261.7 29.1% -31.3 -1.6 -14.5 -15.3	239.3 499.1 27.7% -83.3 -2.9 -7.9 -72.5	122.5 207.9 22.7% -93.7 -2.1 -37.9 -53.6	361.8 707.0 26.0% -177.1 -5.0 -45.8 -126.2	60.5 206.0 21.8% -102.2 -3.2 -20.9 -78.0	183.0 413.9 22.3% -195.9 -5.4 -58.8 -131.7	913.0 25.0% -279.2 -8.3 -66.7 -204.2	236.6 25.5% -0.7 0.0 -10.0 9.3	255.3 26.7% -6.5 -0.1 1.7 -8.1	491.9 26.1% -7.2 -0.1 -8.3 1.2	25.5% 27.4 -0.2 -3.6 31.1	25.9% 20.2 -0.3 -11.9 32.3	24.8% 36.5 2.5 3.1 30.8	25.2% 25 63.8 2.4 -0.5 61.9	3.6 YoY % 2.3 Acquis 3.8 Fx % 3.1 Organ	sitions %	-0.4%	-0.5% -4.9%	-0.5% -1.4%	-0.7% -12.6%	-0.6% -5.2%	-1.1% -6.8%	-32.1% -0.9% -9.6%	-23.4% -0.7% -5.6%	-0.3% 0.0% -4.2%	-2.5% 0.0% 0.7%	-1.4% 0.0% -1.7%	13.2% -0.1% -1.7%	2.9% 0.0% -1.7%	17.7% 15 1.2% 0 1.5% -0	i.4% 6.2% 0.6% 0.2%
Fx Δ Organic Δ Electronics % Margin YoY Δ Acquisitions Δ Fx Δ	4.9 55.6 237.3 26.4% -52.0 -1.3 6.6	183.8 261.7 29.1% -31.3 -1.6 -14.5 -15.3	239.3 499.1 27.7% -83.3 -2.9 -7.9 -72.5 -264.5	122.5 207.9 22.7% -93.7 -2.1 -37.9	361.8 707.0 26.0% -177.1 -5.0 -45.8	60.5 206.0 21.8% -102.2 -3.2 -20.9	183.0 413.9 22.3% -195.9 -5.4 -58.8	913.0 25.0% -279.2 -8.3 -66.7	236.6 25.5% -0.7 0.0 -10.0	255.3 26.7% -6.5 -0.1 1.7	491.9 26.1% -7.2 -0.1 -8.3	25.5% 27.4 -0.2 -3.6	25.9% 20.2 -0.3 -11.9	24.8% 36.5 2.5 3.1	25.2% 25 63.8 2.4 -0.5 61.9 -259.1 -4	3.6 YoY % 2.3 Acquis 3.8 Fx % 3.1 Organ	sitions %	-0.4% 2.3%	-0.5% -4.9% -5.2%	-0.5% -1.4% -12.5%	-0.7% -12.6% -17.8%	-0.6% -5.2% -14.3%	-1.1% -6.8% -25.3%	-32.1% -0.9% -9.6% -21.6%	-23.4% -0.7% -5.6% -17.1%	-0.3% 0.0% -4.2% 3.9%	-2.5% 0.0% 0.7% -3.1%	-1.4% 0.0% -1.7% 0.2%	13.2% -0.1% -1.7% 15.0%	2.9% 0.0% -1.7% 4.6%	17.7% 15 1.2% 0 1.5% -0 14.9% 15	5.4% 6.2% 0.6% 0.2% 0.1% -1.0%

Due to rounding the sum of individual values may not add up to totals presented.

Income Statement Merck KGaA, Darmstadt, Germany	,																							
Group					2023							202								Change				
€ million	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY
Net sales	5.293.0	5,302.4	10,595.3	5,173.1	15.768.4	5.224.5	10.397.6	20,992.9	5.119.8	5,352.2	10,472.0	5.266.1	15 738 0	5.417.7	10 683 8	21.155.8	-3.3%	0.9%	-1.2%	1.8%	-0.2%	3.7%	2.8%	0.8%
Cost of sales	-1.972.5	-2.138.9	-4.111.4	-2.161.8	-6.273.2	-2.327.3	-4.489.1	-8.600.5	-2,110.6	_	-4.229.8	-2,122.0	-6.351.8	-2.319.3	-4.441.3	-8.671.1	7.0%	-0.9%	2.9%	-1.8%	1.3%	-0.3%	-1.1%	0.8%
thereof amortization of intangible assets	-48.2	-46.2	-94.3	-40.3	-134.7	-38.6	-78.9	-173.2	-38.2	-33.1	-71.3	-28.5	-99.8	-31.4	-60.0	-131.3	-20.6%	-28.4%	-24.4%	-29.3%	-25.9%	-18.5%	-24.0%	-24.2%
Gross profit	3.320.4		6.483.9	3.011.3		2.897.2	5.908.5	12,392.4	3.009.2		6.242.1	3.144.0	9.386.2	3,098.4	6.242.5	12.484.6	-9.4%	2.2%	-3.7%	4.4%	-1.1%	6.9%	5.7%	0.7%
in % of net sales	62.7%	59.7%	61.2%	58.2%	60.2%	55.5%	56.8%	59.0%	58.8%	60.4%	59.6%	59.7%	59.6%	57.2%	58.4%	59.0%								
SG&A	-1.688.2	-1.593.6	-3.281.8			-1.609.3	-3.056.3	-6,338.1		-1.793.3	-3.290.6	-1,523.2	-4.813.8	-1,746.8	-3,270.0	-6.560.6	-11.3%	12.5%	0.3%	5.3%	1.8%	8.5%	7.0%	3.5%
in % of net sales	31.9%	30.1%	31.0%	28.0%	30.0%	30.8%	29.4%	30.2%	29.2%	33.5%	31.4%	28.9%	30.6%	32.2%	30.6%	31.0%								
Marketing and selling expenses	-1,109.1	-1,139.4	-2,248.5	-1,104.3	-3,352.9	-1,157.5	-2,261.8	-4,510.4	-1,087.1	-1,145.9	-2,233.0	-1,100.8	-3,333.7	-1,202.6	-2,303.4	-4,536.4	-2.0%	0.6%	-0.7%	-0.3%	-0.6%	3.9%	1.8%	0.6%
thereof amortization of intangible assets (M&S)	-151.3	-148.9	-300.2	-146.7	-446.9	-149.3	-296.0	-596.2	-144.7	-145.3	-290.0	-137.0	-427.0	-140.6	-277.6	-567.6	-4.3%	-2.4%	-3.4%	-6.7%	-4.5%	-5.8%	-6.2%	-4.8%
Administration expenses	-357.9	-345.0	-702.9	-312.0	-1,014.9	-377.4	-689.4	-1,392.3	-331.7	-336.1	-667.8	-309.1	-977.0	-392.6	-701.7	-1,369.6	-7.3%	-2.6%	-5.0%	-0.9%	-3.7%	4.0%	1.8%	-1.6%
Impairment losses and reversals (IFRS 9)	-2.2	-9.7	-11.9	-28.3	-40.2	-10.3	-38.6	-50.5	1.0	0.1	1.1	-2.3	-1.2	-7.2	-9.5	-8.4	n.m.	n.m.	n.m.	-92.0%	-97.1%	-29.8%	-75.5%	-83.4%
Other operating expenses/income	-219.0	-99.4	-318.4	-2.3	-320.8	-64.1	-66.5	-384.9	-79.5	-311.4	-390.8	-111.1	-501.9	-144.3	-255.4	-646.2	-63.7%	213.2%	22.7%	>1.000%	56.5%	125.1%	284.3%	67.9%
Impairments**	-9.7	-36.9	-46.6	-3.8	-50.4	-36.9	-40.7	-87.2	-0.5	-222.2	-222.7	-1.9	-224.6	-52.8	-54.7	-277.4	-95.1%	502.8%	378.1%	-50.4%	345.8%	43.3%	34.5%	217.9%
Research and development costs	-597.3	-600.4	-1,197.7	-581.1	-1,778.8	-666.5	-1,247.5	-2,445.2	-580.6	-647.4	-1,227.9	-523.7	-1,751.6	-527.5	-1,051.2	-2,279.1	-2.8%	7.8%	2.5%	-9.9%	-1.5%	-20.9%	-15.7%	-6.8%
in % of net sales	11.3%	11.3%	11.3%	11.2%	11.3%	12.8%	12.0%	11.6%	11.3%	12.1%	11.7%	9.9%	11.1%	9.7%	9.8%	10.8%								
thereof amortization of intangible assets (R&D)	-4.4	-3.0	-7.4	-3.2	-10.6	-3.4	-6.5	-14.0	-3.3	-3.3	-6.6	-3.3	-9.9	-5.6	-8.9	-15.5	-25.6%	9.8%	-11.2%	4.1%	-6.6%	67.6%	36.8%	11.2%
EBIT	1,035.0	969.5	2,004.4	983.2	2,987.7	621.5	1,604.7	3,609.1	931.3	792.3	1,723.6	1,097.1	2,820.7	824.2	1,921.3	3,644.9	-10.0%	-18.3%	-14.0%	11.6%	-5.6%	32.6%	19.7%	1.0%
in % of net sales	19.6%	18.3%	18.9%	19.0%	18.9%	11.9%	15.4%	17.2%	18.2%	14.8%	16.5%	20.8%	17.9%	15.2%	18.0%	17.2%								
Depreciation and amortization	455.5	482.3	937.8	435.2	1,373.0	506.7	941.9	1,879.7	453.5	680.1	1,133.6	449.3	1,582.9	550.8	1,000.1	2,133.8	-0.4%	41.0%	20.9%	3.2%	15.3%	8.7%	6.2%	13.5%
EBITDA	1,490.5	1,451.8	2,942.3	1,418.4	4,360.7	1,128.2	2,546.6	5,488.9	1,384.8	1,472.5	2,857.3	1,546.4	4,403.7	1,375.0	2,921.4	5,778.7	-7.1%	1.4%	-2.9%	9.0%	1.0%	21.9%	14.7%	5.3%
in % of net sales	28.2%	27.4%	27.8%	27.4%	27.7%	21.6%	24.5%	26.1%	27.0%	27.5%	27.3%	29.4%	28.0%	25.4%	27.3%	27.3%								
EBITDA pre	1,587.0	1,553.3	3,140.3	1,445.6	.,	1,293.0	2,738.7	5,878.9	1,453.9	1,508.9	2,962.8	1,617.7	4,580.6	1,491.1	3,108.8	6,071.6	-8.4%	-2.9%	-5.7%	11.9%	-0.1%	15.3%	13.5%	3.3%
in % of net sales	30.0%	29.3%	29.6%	27.9%	29.1%	24.7%	26.3%	28.0%	28.4%	28.2%	28.3%	30.7%	29.1%	27.5%	29.1%	28.7%								
Financial result	-22.7	-75.7	-98.4	-46.0	-144.3	19.1	-26.8	-125.2	-32.2	-7.2	-39.4	-54.1	-93.5	-15.0	-69.1	-108.5	42.1%	-90.6%	-60.0%	17.7%	-35.2%	n.m.	157.6%	-13.4%
Profit before income tax from continuing operations	1,012.3	893.8	1,906.1	937.3	,	640.6	1,577.9	3,483.9	899.1	785.2	1,684.3	1,043.0	2,727.3	809.2	1,852.2	3,536.5	-11.2%	-12.1%	-11.6%	11.3%	-4.1%	26.3%	17.4%	1.5%
Income tax	-212.6	-187.7	-400.3	-196.8	-597.1	-53.0	-249.8	-650.1	-199.6	-179.8	-379.4	-231.3	-610.7	-139.9	-371.2	-750.6	-6.1%	-4.2%	-5.2%	17.5%	2.3%	163.8%	48.6%	15.5%
Income tax rate	21.0%	21.0%	21.0%	21.0%	21.0%	8.3%	15.8%	18.7%	22.2%	22.9%	22.5%	22.2%	22.4%	17.3%	20.0%	21.2%								
Profit after tax from continuing operations	799.7	706.1	1,505.8	740.4		587.6	1,328.0	2,833.8	699.5	605.4	1,304.9	811.7	2,116.5	669.3	1,480.9	2,785.8	-12.5%	-14.3%	-13.3%	9.6%	-5.8%	13.9%	11.5%	-1.7%
Profit after tax from discontinued operations	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Profit after tax	799.7	706.1	1,505.8	740.4	2,246.2	587.6	1,328.0	2,833.8	699.5	605.4	1,304.9	811.7	2,116.5	669.3	1,480.9	2,785.8	-12.5%	-14.3%	-13.3%	9.6%	-5.8%	13.9%	11.5%	-1.7%
of which: attributable to Merck KGaA shareholders (796.2	703.6	1.499.8	738.7	2.238.4	585.3	1.323.9	2,823.7	694.2	607.4	1,301.6	808.8	2,110.4	666.2	1.475.0	2,776.6	-12.8%	-13.7%	-13.2%	9.5%	-5.7%	13.8%	11.4%	-1.7%
of which: attributable to non-controlling interests	3.5	2.5	6.0	1.8	7.8	2.3	4.1	10.1	5.2	-2.0	3.3	2.9	6.1	3.1	5.9	9.2	48.4%	n.m.	-45.8%	61.2%	-21.4%	33.1%	45.4%	-9.0%
or which, attributable to hon-controlling interests	0.0	2.0	0.0	1.0	7.0	2.0	4.1	10.1	0.2	-2.0	0.0	2.5	0.1	0.1	0.5	J.2	40.470		-40.070	01.270	-21.470	00.170	40.470	-3.070
EPS in €	1.83	1.62	3.45	1.70	5.15	1.35	3.05	6.49	1.60	1.40	2.99	1.86	4.85	1.53	3.39	6.39	-12.6%	-13.6%	-13.3%	9.4%	-5.8%	13.3%	11.1%	-1.5%
thereof from continuing operations	1.83	1.62	3.45	1.70	5.15	1.35	3.05	6.49	1.60	1.40	2.99	1.86	4.85	1.53	3.39	6.39	-12.6%	-13.6%	-13.3%	9.4%	-5.8%	13.3%	11.1%	-1.5%
thereof from discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
EPS pre in €*	2.36	2.20	4.57	2.07	6.64	1.85	3.92	8.49	2.06	2.20	4.26	2.30	6.56	2.07	4.37	8.63	-12.7%	0.0%	-6.8%	11.1%	-1.2%	11.9%	11.5%	1.6%
Number of theoretical shares in million	434.8	434.8	434.8	434.8	434.8	434.8	434.8	434.8	434.8	434.8	434.8	434.8	434.8	434.8	434.8	434.8								
Reconciliation to EBITDA pre																								
EBITDA	1,490.5	1,451.8	2,942.3	1,418.4	4,360.7	1,128.2	2,546.6	5,488.9	1,384.8	1,472.5	2,857.3	1546.4	4,403.7	1,375.0	2,921.4	5,778.7	-7.1%	1.4%	-2.9%	9.0%	1.0%	21.9%	14.7%	5.3%
Adjustments	.,	,,	_,	,	.,	.,	2,0.0.0	2,.22.0	.,	,	_,		,	.,	.,		,			2.270				2.2.9
thereof: Cost of Sales	2.7	4.6	7.2	10.4	17.6	24.9	35.3	42.6	4.1	5.3	9.4	2.1	11.5	29.4	31.5	40.9	53.8%	16.6%	30.3%	-80.1%	-34.8%	18.0%	-10.9%	-3.9%
thereof: Marketing and selling expenses	-0.9	5.4	4.5	8.0	12.4	31.9	39.9	44.3	9.1	2.5	11.6	-1.2	10.4	20.1	18.9	30.4	n.m.	-54.1%	157.6%	n.m.	-16.8%	-37.0%	-52.6%	-31.3%
thereof: Administration expenses	71.7	41.9	113.6	33.9	147.5	98.3	132.2	245.8	43.0	29.8	72.8	30.9	103.7	50.0	80.9	153.7	-40.0%	-28.9%	-35.9%	-8.8%	-29.7%	-49.1%	-38.8%	-37.5%
thereof: Other operating expenses/income	30.9	42.1	73.0	-25.5	47.5	2.9	-22.6	50.5	7.5	-6.1	1.5	36.8	38.3	19.0	55.8	57.3	-75.7%	n.m.	-98.0%	n.m.	-19.4%	546.1%	n.m.	13.6%
thereof: Research and development	-7.9	7.6	-0.3	0.5	0.1	6.8	7.2	6.9	5.4	4.9	10.3	2.7	13.0	-2.5	0.2	10.5	n.m.	-35.0%	n.m.	489.9%	>1.000%	n.m.	-96.6%	52.5%
Total	96.5	101.5	198.0	27.2	225.2	164.9	192.1	390.1	69.1	36.5	105.5	71.4	176.9	116.0	187.4	292.9	-28.4%	-64.1%	-46.7%	162.0%	-21.5%	-29.6%	-2.4%	-24.9%
EBITDA pre	1,587.0	1,553.3	3,140.3	1,445.6	4,585.9	1,293.0	2,738.7	5,878.9	1,453.9	1,508.9	2,962.8	1617.7	4,580.6	1,491.1	3,108.8	6,071.6	-8.4%	-2.9%	-5.7%	11.9%	-0.1%	15.3%	13.5%	3.3%

Due to rounding the sum of individual values may not add up to totals presented.
*For continuing operations.
** Only reflects impairments classified as adjustments.

Reconciliation to EBITDA, EBITDA pre and EPS pre																								
Group				2023								2024								Change	e YoY			
€ million	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY
a) Reconciliation to EBITDA and EBITDA pre																								
EBITDA																								
EBIT	1.035.0	969.5	2.004.4	983.2	2.987.7	621.5	1,604.7	3.609.1	931.3	792.3	1.723.6	1.097.1	2.820.7	824.2	1.921.3	3,644.9	-10.0%	-18.3%	-14.0%	11.6%	-5.6%	32.6%	19.7%	1.0%
Depreciation and amortization	455.5	482.3	937.8	435.2	1.373.0	506.7	941.9	1.879.7	453.5	680.1	1,723.6	449.3	1.582.9	550.8	1,921.3	2.133.8	-0.4%	41.0%	20.9%	3.2%	15.3%	8.7%	6.2%	13.5%
•					,											,	6.5%	9.2%			9.2%	11.9%		9.9%
Regular depreciation and amortization*	242.0	243.2	485.2	241.1	726.3	266.9	508.0	993.2	257.6	265.6	523.2	269.8	793.1	298.6	568.5	1,091.7			7.8%	11.9%			11.9%	
Impairments not adjusted	0.0	4.2	4.2	0.0	4.2	11.8	11.8	16.0	9.2	10.6	19.8	8.7	28.6	21.7	30.5	50.3	>1.000%	153.4%		>1.000%	579.7%	84.5%	158.7%	214.8%
Amortization of purchased intangible assets	203.8	198.1	401.9	190.3	592.2	191.2	381.5	783.3	186.2	181.7	367.9	168.8	536.7	177.6	346.5	714.4	-8.6%	-8.3%	-8.5%	-11.3%	-9.4%	-7.1%	-9.2%	-8.8%
Impairments (net)**	9.7	36.9	46.6	3.8	50.4	36.9	40.7	87.2	0.5	222.2	222.7	1.9	224.6	52.8	54.7	277.4	-95.1%	502.8%	378.1%	-50.4%	345.8%	43.3%	34.5%	217.9%
Total	1,490.5	1,451.8	2,942.3	1,418.4	4,360.7	1,128.2	2,546.6	5,488.9	1,384.8	1,472.5	2,857.3	1,546.4	4,403.7	1,375.0	2,921.4	5,778.7	-7.1%	1.4%	-2.9%	9.0%	1.0%	21.9%	14.7%	5.3%
Adjustments																								
Acquisition costs	9.2	4.8	14.0	3.7	17.7	8.0	4.4	18.5	2.5	0.4	2.9	5.5	8.4	17.2	22.7	25.6	-72.7%	-92.4%	-79.4%	51.6%			411.0%	38.7%
Restructuring costs	44.3	39.3	83.6	24.6	108.2	140.3	164.9	248.5	44.6	34.1	78.7	37.2	115.9	27.6	64.8	143.5	0.7%	-13.3%	-5.9%	51.4%	7.1%	-80.3%	-60.7%	-42.3%
Integration costs/IT costs	23.5	27.1	50.6	28.8	79.4	39.0	67.8	118.4	17.4	21.2	38.6	21.7	60.2	42.4	64.1	102.7	-26.1%	-21.7%	-23.7%	-24.8%	-24.1%	8.9%	-5.4%	-13.3%
Gain (-)/ losses (+) on the divestment of businesses	0.3	17.1	17.4	-48.8	-31.4	-20.1	-68.8	-51.4	-4.8	-51.7	-56.5	0.3	-56.2	9.7	10.0	-46.5	n.m.	n.m.	n.m.	n.m.	79.1%	n.m.	n.m.	-9.6%
Other one-time costs	19.2	13.2	32.4	18.9	51.3	4.8	23.7	56.1	9.4	32.5	41.9	6.6	48.5	19.1	25.7	67.6	-51.2%	146.4%	29.3%	-65.2%	-5.5%	296.8%	8.3%	20.4%
Total	96.5	101.5	198.0	27.2	225.2	164.9	192.1	390.1	69.1	36.5	105.5	71.4	176.9	116.0	187.4	292.9	-28.4%	-64.1%	-46.7%	162.0%	-21.5%	-29.6%	-2.4%	-24.9%
EBITDA pre	1,587.0	1,553.3	3,140.3	1,445.6	4,585.9	1,293.0	2,738.7	5,878.9	1,453.9	1,508.9	2,962.8	1,617.7	4,580.6	1,491.1	3,108.8	6,071.6	-8.4%	-2.9%	-5.7%	11.9%	-0.1%	15.3%	13.5%	3.3%
b) Reconciliation to EPS pre																								
Reconciliation starting from EBITDA pre																								
EBITDA pre	1,587.0	1,553.3	3,140.3	1,445.6	4,585.9	1,293.0	2,738.7	5,878.9	1,453.9	1,508.9	2,962.8	1,617.7	4,580.6	1,491.1	3,108.8	6,071.6	-8.4%	-2.9%	-5.7%	11.9%	-0.1%	15.3%	13.5%	3.3%
Regular depreciation and amortization*	-242.0	-243.2	-485.2	-241.1	-726.3	-266.9	-508.0	-993.2	-257.6	-265.6	-523.2	-269.8	-793.1	-298.6	-568.5	-1,091.7	6.5%	9.2%	7.8%	11.9%	9.2%	11.9%	11.9%	9.9%
Impairments not adjusted	0.0	-4.2	-4.2	0.0	-4.2	-11.8	-11.8	-16.0	-9.2	-10.6	-19.8	-8.7	-28.6	-21.7	-30.5	-50.3	>1.000%	153.4%		>1.000%	579.7%	84.5%	158.7%	214.8%
Financial result	-22.7	-75.7	-98.4	-46.0	-144.3	19.1	-26.8	-125.2	-32.2	-7.2	-39.4	-54.1	-93.5	-15.0	-69.1	-108.5	42.1%	-90.6%	-60.0%	17.7%	-35.2%	n.m.	157.6%	-13.4%
Adjustments within Financial result	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0								
Profit before income tax pre	1,322.3	1,230.2	2,552.5	1,158.5	3,711.1	1,033.5	2,192.1	4,744.6	1,154.8	1,225.5	2,380.4	1,285.1	3,665.4	1,155.7	2,440.7	4,821.1	-12.7%	-0.4%	-6.7%	10.9%	-1.2%	11.8%	11.3%	1.6%
Income tax pre	-290.9	-270.6	-561.6	-254.9	-816.4	-227.4	-482.3	-1,043.8	-254.1	-269.6	-523.7	-282.7	-806.4	-254.3	-537.0	-1,060.6	-12.7%	-0.4%	-6.7%	10.9%	-1.2%	11.8%	11.3%	1.6%
underlying tax rate	22.0%	22.0%	22.0%	22.0%	22.0%	22.0%	22.0%	22.0%	22.0%	22.0%	22.0%	22.0%	22.0%	22.0%	22.0%	22.0%								
Non-controlling interest	-3.5	-2.5	-6.0	-1.8	-7.8	-2.3	-4.1	-10.1	-5.2	2.0	-3.3	-2.9	-6.1	-3.1	-5.9	-9.2	48.4%	n.m.	-45.8%	61.2%	-21.4%	33.1%	45.4%	-9.0%
Net income pre	1,027.9	957.1	1,984.9	901.9	2,886.8	803.9	1,705.7	3,690.7	895.6	957.9	1,853.4	999.5	2,852.9	898.4	1,897.8	3,751.3	-12.9%	0.1%	-6.6%	10.8%	-1.2%	11.8%	11.3%	1.6%
EPS pre in €***	2.36	2.20	4.57	2.07	6.64	1.85	3.92	8.49	2.06	2.20	4.26	2.30	6.56	2.07	4.37	8.63	-12.7%	0.0%	-6.8%	11.1%	-1.2%	11.9%	11.5%	1.6%
2) Reconciliation starting from Profit before tax							_																	
Profit before income tax	1,012.3	893.8	1,906.1	937.3	2,843.3	640.6	1,577.9	3,483.9	899.1	785.2	1,684.3	1,043.0	2,727.3	809.2	1,852.2	3,536.5	-11.2%	-12.1%	-11.6%	11.3%	-4.1%	26.3%	17.4%	1.5%
Amortization of purchased intangible assets	203.8	198.1	401.9	190.3	592.2	191.2	381.5	783.3	186.2	181.7	367.9	168.8	536.7	177.6	346.5	714.4	-8.6%	-8.3%	-8.5%	-11.3%	-9.4%	-7.1%	-9.2%	-8.8%
Impairments**	9.7	36.9	46.6	3.8	50.4	36.9	40.7	87.2	0.5	222.2	222.7	1.9	224.6	52.8	54.7	277.4	-95.1%	502.8%	378.1%	-50.4%	345.8%	43.3%	34.5%	217.9%
Adjustments							_																	
Acquisition costs	9.2	4.8	14.0	3.7	17.7	8.0	4.4	18.5	2.5	0.4	2.9	5.5	8.4	17.2	22.7	25.6	-72.7%	-92.4%	-79.4%	51.6%	-52.3%	>1.000%	411.0%	38.7%
Restructuring costs	44.3	39.3	83.6	24.6	108.2	140.3	164.9	248.5	44.6	34.1	78.7	37.2	115.9	27.6	64.8	143.5	0.7%	-13.3%	-5.9%	51.4%	7.1%	-80.3%	-60.7%	-42.3%
Integration costs/IT costs	23.5	27.1	50.6	28.8	79.4	39.0	67.8	118.4	17.4	21.2	38.6	21.7	60.2	42.4	64.1	102.7	-26.1%	-21.7%	-23.7%	-24.8%	-24.1%	8.9%	-5.4%	-13.3%
Gain (-)/ losses (+) on the divestment of businesses	0.3	17.1	17.4	-48.8	-31.4	-20.1	-68.8	-51.4	-4.8	-51.7	-56.5	0.3	-56.2	9.7	10.0	-46.5	n.m.	n.m.	n.m.	n.m.	79.1%	n.m.	n.m.	-9.6%
Other one-time costs	19.2	13.2	32.4	18.9	51.3	4.8	23.7	56.1	9.4	32.5	41.9	6.6	48.5	19.1	25.7	67.6	-51.2%	146.4%	29.3%	-65.2%	-5.5%	296.8%	8.3%	20.4%
Adjustments within Financial result	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0								
Total adjustments	96.5	101.5	198.0	27.2	225.2	164.9	192.1	390.1	69.1	36.5	105.5	71.4	176.9	116.0	187.4	292.9	-28.4%	-64.1%	-46.7%	162.0%	-21.5%	-29.6%	-2.4%	-24.9%
Profit before income tax pre	1,322.3	1,230.2	2,552.5	1,158.5	3,711.1	1,033.5	2,192.1	4,744.6	1,154.8	1,225.5	2,380.4	1,285.1	3,665.4	1,155.7	2,440.7	4,821.1	-12.7%	-0.4%	-6.7%	10.9%	-1.2%	11.8%	11.3%	1.6%
Income tax pre	-290.9	-270.6	-561.6	-254.9	-816.4	-227.4	-482.3	-1,043.8	-254.1	-269.6	-523.7	-282.7	-806.4	-254.3	-537.0	-1,060.6	-12.7%	-0.4%	-6.7%	10.9%	-1.2%	11.8%	11.3%	1.6%
underlying tax rate	22.0%	22.0%	22.0%	22.0%	22.0%	22.0%	22.0%	22.0%	22.0%	22.0%	22.0%	22.0%	22.0%	22.0%	22.0%	22.0%								
Total costs excluded from Net income	231.7	253.5	485.2	163.2	648.4	218.6	381.8	867.0	201.3	350.5	551.8	190.7	742.5	232.2	422.8	974.7	-13.1%	38.3%	13.7%	16.8%	14.5%	6.2%	10.7%	12.4%
Total costs excluded from EPS in €	0.53	0.58	1.12	0.38	1.49	0.50	0.88	1.99	0.46	0.81	1.27	0.44	1.71	0.53	0.97	2.24	-13.2%	39.7%	13.4%	15.8%	14.8%	6.0%	10.2%	12.6%
Non-controlling interest	-3.5	-2.5	-6.0	-1.8	-7.8	-2.3	-4.1	-10.1	-5.2	2.0	-3.3	-2.9	-6.1	-3.1	-5.9	-9.2	48.4%	n.m.	-45.8%	61.2%	-21.4%	33.1%	45.4%	-9.0%
Net income pre	1,027.9	957.1	1,984.9	901.9	2,886.8	803.9	1,705.7	3,690.7	895.6	957.9	1,853.4	999.5	2,852.9	898.4	1,897.8	3,751.3	-12.9%	0.1%	-6.6%	10.8%	-1.2%	11.8%	11.3%	1.6%
EPS pre in €***	2.36	2.20	4.57	2.07	6.64	1.85	3.92	8.49	2.06	2.20	4.26	2.30	6.56	2.07	4.37	8.63	-12.7%	0.0%	-6.8%	11.1%	-1.2%	11.9%	11.5%	1.6%
Non-ben-fabranatical above to 1999	40.4.6	404.0	404.0	404.0	404.0	404.0	4040	404.0	404.0	404.0	404.0	40.4.0	404.0	404.0	404.0	404.0								
Number of theoretical shares in million	434.8	434.8	434.8	434.8	434.8	434.8	434.8	434.8	434.8	434.8	434.8	434.8	434.8	434.8	434.8	434.8								

Due to rounding the sum of individual values may not add up to totals presented.

* Regular depreciation and amortization = Depreciation and amortization - Amortization of purchased intangible assets - Impairments.

*** Only reflects impairments classified as adjustments.

**** For continuing operations.

Breakdown of depreciation and amortization	on and adjustm	nents																						
Group					20	023							202	4						Change	e YoY			
€ million	Division	Q1	Q2	H1	Q3	9М	Q4	H2	FY	Q1	Q2	H1	Q3	9М	Q4	H2	Y C	1 Q:	2 H1	Q3	9M	Q4	H2	FY
a) Depreciation and amortization																								
Regular depreciation and amortization*	all	242.0	243.2	485.2	241.1	726.3	266.9	508.0	993.2	257.6	265.6	523.2	269.8	793.1	298.6	568.5 1,09°			7.8%	11.9%	9.2%	11.9%	11.9%	9.9%
Impairments not adjusted	all	0.0	4.2	4.2	0.0	4.2	11.8	11.8	16.0	9.2	10.6	19.8	8.7	28.6	21.7	30.5 5	.3 >1.000°	153.4%	371.8%	>1.000%	579.7%	84.5%	158.7%	214.8%
Amortization of purchased intangible asset	ts																							
Life Science	LS	118.2	115.8	234.0	108.5	342.5	108.8	217.3	451.3	107.8	108.4	216.3	99.7	316.0	109.2	208.9 42				-8.1%	-7.7%	0.4%	-3.9%	-5.8%
Healthcare	HC	1.5	1.6	3.2	1.7	4.8	1.7	3.3	6.5	1.6	1.6	3.2	1.6	4.8	1.5	3.1	.4 3.79	6 -0.9%	5 1.3%	-4.1%	-0.6%	-7.1%	-5.6%	-2.2%
Electronics	EL	84.1	80.6	164.7	80.1	244.8	80.8	160.8	325.6	76.8	71.7	148.4	67.5	215.9	66.9	134.5 283	.9 -8.79			-15.7%	-11.8%	-17.1%	-16.4%	-13.1%
Total		203.8	198.1	401.9	190.3	592.2	191.2	381.5	783.3	186.2	181.7	367.9	168.8	536.7	177.6	346.5 714	.4 -8.6°	6 -8.3%	-8.5%	-11.3%	-9.4%	-7.1%	-9.2%	-8.8%
Impairments (net)**	all	9.7	36.9	46.6	3.8	50.4	36.9	40.7	87.2	0.5	222.2	222.7	1.9	224.6	52.8	54.7 27	.4 -95.19	502.8%	378.1%	-50.4%	345.8%	43.3%	34.5%	217.9%
Total depreciation and amortization		455.5	482.3	937.8	435.2	1,373.0	506.7	941.9	1,879.7	453.5	680.1	1,133.6	449.3	1,582.9	550.8	1,000.1 2,13	.8 -0.49	41.0%	20.9%	3.2%	15.3%	8.7%	6.2%	13.5%
b) Adjustments																								
Acquisition costs		9.2	4.8	14.0	3.7	17.7	0.8	4.4	18.5	2.5	0.4	2.9	5.5	8.4	17.2	22.7 2	.6 -72.79	-92.4%	-79.4%	51.6%	-52.3%	>1.000%	411.0%	38.7%
Restructuring costs																								
Life Science	LS	0.4	1.8	2.2	4.3	6.5	23.1	27.4	29.6	18.0	8.6	26.6	14.3	40.9	32.4	46.7 7	.4 >1.0009	365.9%	>1.000%	235.3%	528.1%	40.2%	70.6%	147.5%
Healthcare	HC	-7.3	12.0	4.7	2.6	7.3	24.2	26.8	31.6	5.3	2.3	7.6	3.1	10.7	-2.6	0.5	.1 n.n	81.2%	60.9%	19.5%	46.2%	n.m.	-98.1%	-74.4%
Electronics	EL	2.2	6.9	9.1	9.9	18.9	41.0	50.9	60.0	4.1	4.2	8.3	7.8	16.1	5.9	13.7 2	.0 88.89	-39.4%	-8.9%	-20.7%	-15.1%	-85.6%	-73.0%	-63.3%
Corporate and Other	CO	49.0	18.5	67.6	7.9	75.4	52.0	59.8	127.4	17.2	19.1	36.3	12.0	48.2	-8.1	3.8 4	.1 -65.09	2.9%	-46.4%	52.3%	-36.1%	n.m.	-93.6%	-68.5%
Total		44.3	39.3	83.6	24.6	108.2	140.3	164.9	248.5	44.6	34.1	78.7	37.2	115.9	27.6	64.8 14	.5 0.79	-13.3%	-5.9%	51.4%	7.1%	-80.3%	-60.7%	-42.3%
Integration costs/IT costs																	_							
Integration Cost	LS/EL/CO	1.9	2.0	4.0	2.2	6.1	1.4	3.5	7.5	2.3	2.1	4.4	-1.0	3.4	8.0	7.0 1	.4 18.49	4.0%	11.0%	n.m.	-44.2%	481.4%	97.2%	51.6%
ERP/HR systems	all	21.6	25.0	46.6	26.7	73.2	37.6	64.3	110.9	15.1	19.1	34.2	22.7	56.8	34.5	57.1 9	.3 -30.19	-23.8%	-26.7%	-15.0%	-22.4%	-8.3%	-11.1%	-17.6%
Total		23.5	27.1	50.6	28.8	79.4	39.0	67.8	118.4	17.4	21.2	38.6	21.7	60.2	42.4	64.1 103	.7 -26.19	-21.7%	-23.7%	-24.8%	-24.1%	8.9%	-5.4%	-13.3%
Gain (-)/ losses (+) on the divestment of but	sinesses																							
Costs related to former business activities	CO	0.0	21.0	21.0	-3.0	18.0	-16.6	-19.6	1.4	0.0	-18.6	-18.6	0.0	-18.6	0.0	0.0 -1	.6 n.n	. n.m	. n.m.	-100.0%	n.m.	-100.0%	-100.0%	n.m.
Costs related to former business activities	EL	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.4	1.4	0.0	1.4	15.2	15.2	.5 n.n	. n.m	. n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Sale of CH, Allergopharma and others	HC	0.3	-3.9	-3.6	-45.8	-49.4	-3.4	-49.2	-52.8	-4.8	-34.5	-39.3	0.0	-39.3	-5.9	-5.9 -4	.2 n.n	. 786.9%	>1.000%	n.m.	-20.4%	72.0%	-88.0%	-14.4%
Costs related to former business activities	LS	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.3	0.5	0.8	.8 n.n	. n.m	. n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Total		0.3	17.1	17.4	-48.8	-31.4	-20.1	-68.8	-51.4	-4.8	-51.7	-56.5	0.3	-56.2	9.7	10.0 -4	.5 n.n	. n.m	. n.m.	n.m.	79.1%	n.m.	n.m.	-9.6%
Other one-time costs																								
	HC	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	.0 n.n	. n.m	. n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Others	LS	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	.0 n.n	. n.m	. n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Outers	EL	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	.0 n.n	. n.m	. n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
	CO	19.2	13.2	32.4	18.9	51.3	4.8	23.7	56.1	9.4	32.5	41.9	6.6	48.5	19.1	25.7 6	.6 -51.29	146.4%	29.3%	-65.2%	-5.5%	296.8%	8.3%	20.4%
Total		19.2	13.2	32.4	18.9	51.3	4.8	23.7	56.1	9.4	32.5	41.9	6.6	48.5	19.1		.6 -51.2°			-65.2%	-5.5%	296.8%	8.3%	20.4%
Total adjustments		96.5	101.5	198.0	27.2	225.2	164.9	192.1	390.1	69.1	36.5	105.5	71.4	176.9	116.0	187.4 29:	.9 -28.49	-64.1%	-46.7%	162.0%	-21.5%	-29.6%	-2.4%	-24.9%

^{*} Regular depreciation and amortization = Depreciation and amortization - Amortization of purchased intangible assets - Impairments

^{**} Only reflects impairments classified as adjustments.

Income Statement Merck KGaA, Darmstadt, German	ıy																							
Life Science				20	23							2	024							Change	YoY			
€ million	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9М	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY
Net sales	2,486.8	2,353.5	4,840.3	2,190.9	7,031.2	2,249.4	4,440.2	9,280.5	2,143.7	2,258.1	4,401.8	2,209.7	6,611.5	2,304.5	4,514.2	8,916.0	-13.8%	-4.1%	-9.1%	0.9%	-6.0%	2.5%	1.7%	-3.9%
Cost of sales	-999.2	-1,078.2	-2,077.5	-1,031.1	-3,108.6	-1,127.6	-2,158.8	-4,236.3	-987.6	-1,041.9	-2,029.5	-1,008.2	-3,037.6	-1,112.4	-2,120.6	-4,150.1	-1.2%	-3.4%	-2.3%	-2.2%	-2.3%	-1.3%	-1.8%	-2.0%
thereof amortization of intangible assets	-13.3	-13.5	-26.8	-8.3	-35.1	-7.2	-15.4	-42.2	-7.1	-6.9	-14.0	-5.5	-19.5	-11.7	-17.2	-31.2	-46.7%	-48.8%	-47.8%	-33.3%	-44.3%	62.9%	11.4%	-26.1%
Gross profit	1,487.5	1,275.3	2,762.8	1,159.7	3,922.6	1,121.7	2,281.4	5,044.3	1,156.2	1,216.2	2,372.3	1,201.5	3,573.8	1,192.1	2,393.6	4,765.9	-22.3%	-4.6%	-14.1%	3.6%	-8.9%	6.3%	4.9%	-5.5%
in % of net sales	59.8%	54.2%	57.1%	52.9%	55.8%	49.9%	51.4%	54.4%	53.9%	53.9%	53.9%	54.4%	54.1%	51.7%	53.0%	53.5%								
SG&A	-711.3	-720.8	-1,432.2	-673.2	-2,105.4	-692.4	-1,365.7	-2,797.8	-683.3	-749.4	-1,432.7	-698.7	-2,131.5	-739.9	-1,438.7	-2,871.4	-3.9%	4.0%	0.0%	3.8%	1.2%	6.9%	5.3%	2.6%
in % of net sales	28.6%	30.6%	29.6%	30.7%	29.9%	30.8%	30.8%	30.1%	31.9%	33.2%	32.5%	31.6%	32.2%	32.1%	31.9%	32.2%								
Marketing and selling expenses	-567.5	-566.3	-1,133.8	-555.7	-1,689.5	-555.3	-1,110.9	-2,244.7	-550.6	-566.5	-1,117.1	-543.4	-1,660.5	-577.1	-1,120.5	-2,237.6	-3.0%	0.0%	-1.5%	-2.2%	-1.7%	3.9%	0.9%	-0.3%
thereof amortization of intangible assets (M&S)	-101.4	-100.4	-201.8	-98.2	-300.0	-99.5	-197.7	-399.5	-98.7	-99.4	-198.1	-92.1	-290.2	-94.7	-186.8	-385.0	-2.7%	-0.9%	-1.8%	-6.2%	-3.3%	-4.8%	-5.5%	-3.6%
Administration expenses	-105.0	-102.8	-207.7	-102.7	-310.5	-114.6	-217.4	-425.1	-111.9	-104.4	-216.3	-104.1	-320.4	-120.4	-224.5	-440.8	6.6%	1.5%	4.1%	1.3%	3.2%	5.0%	3.3%	3.7%
Impairment losses and reversals (IFRS 9)	-1.1	-1.2	-2.3	-0.1	-2.4	0.3	0.2	-2.1	-1.0	-0.1	-1.1	-6.2	-7.3	0.4	-5.8	-6.9	-4.1%	-90.3%	-50.2%	>1.000%	209.4%	54.7%	n.m.	230.5%
Other operating expenses/income	-37.8	-50.6	-88.3	-14.8	-103.1	-22.8	-37.6	-125.9	-19.7	-78.5	-98.2	-45.0	-143.2	-42.9	-87.9	-186.1	-47.7%	55.2%	11.2%	205.0%	38.9%	87.8%	133.9%	47.8%
Impairments**	0.0	-31.9	-31.9	0.0	-31.9	-1.8	-1.8	-33.7	0.0	-56.0	-56.0	0.0	-56.0	-29.8	-29.8	-85.8	-100.0%	75.5%	75.5%	>1.000%	75.5%	>1.000%	>1.000%	154.3%
Research and development costs	-103.8	-99.1	-203.0	-90.4	-293.3	-103.1	-193.4	-396.4	-95.4	-96.4	-191.8	-92.0	-283.8	-104.0	-196.0	-387.8	-8.1%	-2.7%	-5.5%	1.8%	-3.2%	0.9%	1.3%	-2.2%
in % of net sales	4.2%	4.2%	4.2%	4.1%	4.2%	4.6%	4.4%	4.3%	4.5%	4.3%	4.4%	4.2%	4.3%	4.5%	4.3%	4.3%								
thereof amortization of intangible assets (R&D)	-3.4	-2.0	-5.4	-2.1	-7.5	-2.1	-4.1	-9.5	-2.1	-2.1	-4.2	-2.1	-6.2	-2.7	-4.8	-9.0	-38.9%	4.5%	-22.8%	0.9%	-16.2%	31.6%	16.3%	-5.8%
EBIT	672.4	455.3	1,127.7	396.1	1,523.8	326.2	722.3	1,850.0	377.4	370.3	747.8	410.8	1,158.6	348.2	759.0	1,506.7	-43.9%	-18.7%	-33.7%	3.7%	-24.0%	6.7%	5.1%	-18.6%
in % of net sales	27.0%	19.3%	23.3%	18.1%	21.7%	14.5%	16.3%	19.9%	17.6%	16.4%	17.0%	18.6%	17.5%	15.1%	16.8%	16.9%								
Depreciation and amortization	211.7	243.1	454.8	204.6	659.4	222.0	426.6	881.4	207.4	268.5	475.9	209.7	685.6	262.8	472.5	948.4	-2.0%	10.4%	4.6%	2.5%	4.0%	18.4%	10.8%	7.6%
EBITDA	884.0	698.5	1,582.5	600.7	2,183.3	548.2	1,148.9	2,731.4	584.8	638.8	1,223.7	620.5	1,844.2	610.9	1,231.5	2,455.1	-33.8%	-8.5%	-22.7%	3.3%	-15.5%	11.4%	7.2%	-10.1%
in % of net sales	35.5%	29.7%	32.7%	27.4%	31.1%	24.4%	25.9%	29.4%	27.3%	28.3%	27.8%	28.1%	27.9%	26.5%	27.3%	27.5%								
EBITDA pre	900.6	711.9	1,612.5	615.1	2,227.6	592.0	1,207.1	2,819.6	611.2	654.7	1,265.9	646.4	1,912.4	676.8	1,323.3	2,589.2	-32.1%	-8.0%	-21.5%	5.1%	-14.2%	14.3%	9.6%	-8.2%
in % of net sales	36.2%	30.2%	33.3%	28.1%	31.7%	26.3%	27.2%	30.4%	28.5%	29.0%	28.8%	29.3%	28.9%	29.4%	29.3%	29.0%								
Reconciliation to EBITDA pre																								
EBITDA	884.0	698.5	1,582.5	600.7	2,183.3	548.2	1,148.9	2,731.4	584.8	638.8	1,223.7	620.5	1,844.2	610.9	1,231.5	2,455.1	-33.8%	-8.5%	-22.7%	3.3%	-15.5%	11.4%	7.2%	-10.1%
Adjustments																								
thereof: Cost of Sales	0.2	-0.1	0.1	2.8	3.0	3.2	6.1	6.2	8.0	0.9	1.6	0.7	2.3	22.3	23.0	24.6	276.6%	n.m.	>1.000%	-76.8%	-22.9%	593.3%	280.1%	298.4%
thereof: Marketing and selling expenses	-1.2	0.3	-0.9	0.3	-0.6	12.9	13.2	12.3	5.3	4.0	9.3	-0.8	8.5	16.4	15.6	24.8	n.m.	>1.000%	n.m.	n.m.	n.m.	27.3%	18.3%	102.5%
thereof: Administration expenses	11.1	12.0	23.0	9.0	32.0	20.8	29.8	52.8	17.1	8.3	25.5	5.9	31.4	26.9	32.8	58.3	54.9%	-30.6%	10.5%	-34.5%	-2.2%	29.4%	10.1%	10.2%
thereof: Other operating expenses/income	6.4	0.5	6.9	2.3	9.2	4.6	6.9	13.8	2.6	2.6	5.2	20.0	25.3	0.3	20.3	25.5	-59.8%	459.3%	-24.3%	780.4%	174.7%	-94.4%	193.2%	84.4%
thereof: Research and development	0.0	0.7	0.8	0.0	0.8	2.3	2.3	3.1	0.6	0.1	0.7	0.1	0.8	0.0	0.1	0.8	>1.000%	-86.1%	-11.9%	n.m.	1.9%	-99.6%	-95.1%	-74.5%
Total	16.5	13.4	29.9	14.4	44.4	43.8	58.2	88.2	26.4	15.9	42.2	25.9	68.2	65.9	91.8	134.0	59.4%	18.6%	41.1%	79.6%	53.6%	50.4%	57.6%	52.0%
EBITDA pre	900.6	711.9	1,612.5	615.1	2,227.6	592.0	1,207.1	2,819.6	611.2	654.7	1,265.9	646.4	1,912.4	676.8	1,323.3	2,589.2	-32.1%	-8.0%	-21.5%	5.1%	-14.2%	14.3%	9.6%	-8.2%

^{**} Only reflects impairments classified as adjustments.

Detailed reconciliation - Life Science																								
				20	23								2024							Change				
€ million	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY
EBIT	672.4	455.3	1,127.7	396.1	1,523.8	326.2	722.3	1,850.0	377.4	370.3	747.8	410.8	1,158.6	348.2	759.0	1,506.7	-43.9%	-18.7%	-33.7%	3.7%	-24.0%	6.7%	5.1%	-18.6%
Regular depreciation and amortization*	93.5	95.4	188.9	96.1	285.0	111.4	207.5	396.4	99.5	104.1	203.7	109.8	313.5	122.9	232.8	436.4	6.5%	9.1%	7.8%	14.3%	10.0%	10.3%	12.2%	10.1%
Impairments not adjusted	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.9	1.1	1.1	-100.0%	n.m.	-100.0%	n.m.	n.m.	>1.000%	>1.000%	>1.000%
Amortization of purchased intangible assets	118.2	115.8	234.0	108.5	342.5	108.8	217.3	451.3	107.8	108.4	216.3	99.7	316.0	109.2	208.9	425.1	-8.7%	-6.4%	-7.6%	-8.1%	-7.7%	0.4%	-3.9%	-5.8%
Impairments (net)**	0.0	31.9	31.9	0.0	31.9	1.8	1.8	33.7	0.0	56.0	56.0	0.0	56.0	29.8	29.8	85.8	-100.0%	75.5%	75.5%	>1.000%	75.5%	>1.000%	>1.000%	154.3%
Total depreciation and amortization	211.7	243.1	454.8	204.6	659.4	222.0	426.6	881.4	207.4	268.5	475.9	209.7	685.6	262.8	472.5	948.4	-2.0%	10.4%	4.6%	2.5%	4.0%	18.4%	10.8%	7.6%
EBITDA	884.0	698.5	1,582.5	600.7	2,183.3	548.2	1,148.9	2,731.4	584.8	638.8	1,223.7	620.5	1,844.2	610.9	1,231.5	2,455.1	-33.8%	-8.5%	-22.7%	3.3%	-15.5%	11.4%	7.2%	-10.1%
Adjustments																								
Acquisition costs	5.0	-0.3	4.8	0.0	4.8	0.8	0.8	5.6	1.1	-0.4	0.7	3.5	4.2	9.3	12.9	13.5	-78.4%	71.1%	-86.3%	n.m.	-12.9%	>1.000%	>1.000%	141.8%
Restructuring costs																								
Restructuring costs	0.4	1.8	2.2	4.3	6.5	23.1	27.4	29.6	18.0	8.6	26.6	14.3	40.9	32.4	46.7	73.4	>1.000%	365.9%	>1.000%	235.3%	528.1%	40.2%	70.6%	147.5%
Total	0.4	1.8	2.2	4.3	6.5	23.1	27.4	29.6	18.0	8.6	26.6	14.3	40.9	32.4	46.7	73.4	>1.000%	365.9%	>1.000%	235.3%	528.1%	40.2%	70.6%	147.5%
Integration costs/IT costs																								
Integration Cost	0.7	1.0	1.7	0.9	2.7	8.0	1.7	3.5	1.0	0.6	1.7	0.5	2.2	3.5	4.0	5.7	40.1%	-34.3%	-1.9%	-46.2%	-17.6%	341.4%	131.6%	65.5%
ERP/HR systems	10.3	10.9	21.2	9.2	30.4	19.1	28.3	49.5	6.2	7.1	13.3	7.2	20.6	20.1	27.4	40.7	-40.4%	-34.3%	-37.3%	-21.3%	-32.4%	5.4%	-3.2%	-17.8%
Total	11.1	11.8	22.9	10.1	33.1	19.9	30.0	53.0	7.2	7.8	15.0	7.8	22.7	23.7	31.4	46.4	-35.0%	-34.3%	-34.6%	-23.6%	-31.2%	19.0%	4.6%	-12.4%
Gain (-)/ losses (+) on the divestment of bus	sinesses																							
Costs related to former business activities	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.3	0.5	0.8	0.8	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Total	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.3	0.5	0.8	0.8	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Other one-time costs																								
Others	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Total	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Total adjustments	16.5	13.4	29.9	14.4	44.4	43.8	58.2	88.2	26.4	15.9	42.2	25.9	68.2	65.9	91.8	134.0	59.4%	18.6%	41.1%	79.6%	53.6%	50.4%	57.6%	52.0%
EBITDA pre	900.6	711.9	1,612.5	615.1	2,227.6	592.0	1,207.1	2,819.6	611.2	654.7	1,265.9	646.4	1,912.4	676.8	1,323.3	2,589.2	-32.1%	-8.0%	-21.5%	5.1%	-14.2%	14.3%	9.6%	-8.2%

^{*} Regular depreciation and amortization = Depreciation and amortization - Amortization of purchased intangible assets - Impairments.

^{**} Only reflects impairments classified as adjustments.

Income Statement Merck KGaA, Darmstadt, German	ıy																							
Healthcare				20)23							20	24							Change	: YoY			
€ million	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9М	Q4	H2	FY
Net sales	1,905.5	2,049.5	3,955.0	2,066.3	6,021.3	2,031.9	4,098.2	8,053.2	2,047.7	2,136.7	4,184.4	2,133.4	6,317.8	2,136.7	4,270.1	8,454.5	7.5%	4.3%	5.8%	3.2%	4.9%	5.2%	4.2%	5.0%
Cost of sales	-446.6	-485.9	-932.6	-540.0	-1,472.6	-556.4	-1,096.4	-2,029.0	-543.3	-505.9	-1,049.1	-555.9	-1,605.0	-595.8	-1,151.7	-2,200.8	21.6%	4.1%	12.5%	2.9%	9.0%	7.1%	5.0%	8.5%
thereof amortization of intangible assets	-1.2	-1.2	-2.3	-1.2	-3.5	-1.1	-2.3	-4.6	-1.1	-1.1	-2.3	-1.1	-3.4	-1.1	-2.3	-4.5	-3.0%	-2.4%	-2.7%	-2.0%	-2.5%	-0.5%	-1.3%	-2.0%
Gross profit	1,458.9	1,563.6	3,022.4	1,526.2	4,548.7	1,475.5	3,001.8	6,024.2	1,504.4	1,630.9	3,135.3	1,577.5	4,712.8	1,540.9	3,118.4	6,253.7	3.1%	4.3%	3.7%	3.4%	3.6%	4.4%	3.9%	3.8%
in % of net sales	76.6%	76.3%	76.4%	73.9%	75.5%	72.6%	73.2%	74.8%	73.5%	76.3%	74.9%	73.9%	74.6%	72.1%	73.0%	74.0%								
SG&A	-543.9	-546.4	-1,090.2	-481.7	-1,571.9	-570.7	-1,052.4	-2,142.6	-488.9	-684.6	-1,173.5	-505.8	-1,679.3	-591.2	-1,097.0	-2,270.6	-10.1%	25.3%	7.6%	5.0%	6.8%	3.6%	4.2%	6.0%
in % of net sales	28.5%	26.7%	27.6%	23.3%	26.1%	28.1%	25.7%	26.6%	23.9%	32.0%	28.0%	23.7%	26.6%	27.7%	25.7%	26.9%								
Marketing and selling expenses	-380.6	-422.4	-803.0	-405.5	-1,208.5	-459.1	-864.6	-1,667.6	-398.2	-437.4	-835.6	-415.8	-1,251.4	-461.9	-877.7	-1,713.3	4.6%	3.5%	4.1%	2.6%	3.6%	0.6%	1.5%	2.7%
thereof amortization of intangible assets (M&S)	-0.3	-0.4	-0.7	-0.5	-1.2	-0.5	-0.9	-1.6	-0.4	-0.4	-0.8	-0.4	-1.2	-0.4	-0.8	-1.6	29.2%	3.2%	14.8%	-10.6%	4.8%	-11.3%	-11.0%	0.3%
Administration expenses	-75.5	-79.3	-154.8	-78.8	-233.6	-80.2	-159.0	-313.8	-75.2	-78.4	-153.6	-72.9	-226.6	-86.4	-159.3	-312.9	-0.4%	-1.1%	-0.7%	-7.5%	-3.0%	7.7%	0.2%	-0.3%
Impairment losses and reversals (IFRS 9)	-1.0	-8.4	-9.4	-28.4	-37.8	-3.0	-31.3	-40.8	1.9	1.8	3.8	4.3	8.1	-5.7	-1.4	2.4	n.m.	n.m.	n.m.	n.m.	n.m.	91.3%	-95.5%	n.m.
Other operating expenses/income	-86.8	-36.2	-123.0	30.9	-92.0	-28.4	2.5	-120.5	-17.4	-170.6	-188.0	-21.3	-209.3	-37.3	-58.7	-246.7	-79.9%	371.0%	52.9%	n.m.	127.4%	31.4%	n.m.	104.8%
Impairments**	0.6	0.0	0.6	0.0	0.6	-10.5	-10.5	-9.9	0.0	-155.3	-155.3	0.0	-155.3	-4.9	-4.9	-160.1	-100.0%	n.m.	n.m.	n.m.	n.m.	-53.5%	-53.5%	>1.000%
Research and development costs	-395.3	-401.5	-796.7	-391.3	-1,188.0	-469.0	-860.3	-1,657.0	-397.5	-445.4	-842.9	-329.9	-1,172.8	-329.7	-659.6	-1,502.5	0.6%	11.0%	5.8%	-15.7%	-1.3%	-29.7%	-23.3%	-9.3%
in % of net sales	20.7%	19.6%	20.1%	18.9%	19.7%	23.1%	21.0%	20.6%	19.4%	20.8%	20.1%	15.5%	18.6%	15.4%	15.4%	17.8%								
thereof amortization of intangible assets (R&D)	-0.1	-0.1	-0.1	-0.1	-0.2	-0.1	-0.1	-0.2	-0.1	-0.1	-0.1	-0.1	-0.2	0.0	-0.1	-0.2	0.0%	0.0%	0.0%	5.7%	1.9%	-100.0%	-47.1%	-23.6%
EBIT	519.7	615.8	1,135.5	653.2	1,788.7	435.9	1,089.1	2,224.6	618.0	500.9	1,118.9	741.8	1,860.7	619.9	1,361.7	2,480.6	18.9%	-18.7%	-1.5%	13.6%	4.0%	42.2%	25.0%	11.5%
in % of net sales	27.3%	30.0%	28.7%	31.6%	29.7%	21.5%	26.6%	27.6%	30.2%	23.4%	26.7%	34.8%	29.5%	29.0%	31.9%	29.3%								
Depreciation and amortization	72.9	76.2	149.1	70.2	219.4	100.6	170.9	320.0	88.3	248.5	336.8	87.6	424.4	115.5	203.1	539.9	21.1%	226.0%	125.9%	24.7%	93.5%	14.8%	18.9%	68.7%
EBITDA	592.6	692.0	1,284.6	723.4	2,008.1	536.5	1,259.9	2,544.6	706.3	749.4	1,455.7	829.4	2,285.1	735.4	1,564.8	3,020.5	19.2%	8.3%	13.3%	14.6%	13.8%	37.1%	24.2%	18.7%
in % of net sales	31.1%	33.8%	32.5%	35.0%	33.3%	26.4%	30.7%	31.6%	34.5%	35.1%	34.8%	38.9%	36.2%	34.4%	36.6%	35.7%								
EBITDA pre	589.6	703.6	1,293.2	685.4	1,978.5	564.5	1,249.9	2,543.1	708.0	719.8	1,427.8	835.7	2,263.5	731.2	1,566.9	2,994.6	20.1%	2.3%	10.4%	21.9%	14.4%	29.5%	25.4%	17.8%
in % of net sales	30.9%	34.3%	32.7%	33.2%	32.9%	27.8%	30.5%	31.6%	34.6%	33.7%	34.1%	39.2%	35.8%	34.2%	36.7%	35.4%								
Reconciliation to EBITDA pre																								
EBITDA	592.6	692.0	1.284.6	723.4	2.008.1	536.5	1.259.9	2,544.6	706.3	749.4	1,455.7	829.4	2.285.1	735.4	1.564.8	3,020.5	19.2%	8.3%	13.3%	14.6%	13.8%	37.1%	24.2%	18.7%
Adjustments	302.0	132.0	.,_00	. 20. 1	_,	200.0	.,_00.0	_,_ 1110	. 55.5		.,.50.1	220.1	_,_50	. 30. 1	.,251.0	2,120.0	.0.270	2.070	. 5.070		. 2.070	2,0	/0	. 3 70
thereof: Cost of Sales	0.2	-1.7	-1.5	0.3	-1.3	-0.1	0.2	-1.3	0.1	0.0	0.1	0.0	0.1	0.1	0.1	0.1	-52.4%	-99.6%	n.m.	-97.4%	n.m.	n.m.	-70.9%	n.m.
thereof: Marketing and selling expenses	0.3	4.6	4.9	5.7	10.6	18.3	23.9	28.8	3.7	-1.9	1.7	0.1	1.9	1.4	1.6	3.3	>1.000%	n.m.	-64.5%	-97.5%	-82.2%	-92.1%	-93.4%	-88.5%
thereof: Administration expenses	4.0	3.5	7.4	5.1	12.5	7.6	12.6	20.1	1.1	2.7	3.8	3.6	7.3	4.3	7.9	11.6	-72.0%	-22.9%	-49.2%	-29.6%	-41.2%	-43.0%	-37.7%	-41.9%
thereof: Other operating expenses/income	0.3	0.3	0.6	-49.3	-48.7	-2.3	-51.5	-51.0	-8.0	-34.9	-42.9	-0.1	-43.0	-7.0	-7.1	-50.0	n.m.	n.m.	n.m.	-99.8%	-11.6%	209.8%	-86.2%	-1.8%
thereof: Research and development	-7.8	5.0	-2.8	0.2	-2.6	4.5	4.7	1.9	4.8	4.6	9.4	2.7	12.1	-3.0	-0.4	9.1	n.m.	-8.2%	n.m.	>1.000%	n.m.	n.m.	n.m.	374.9%
Total	-3.0	11.6	8.6	-38.1	-29.5	28.0	-10.1	-1.5	1.7	-29.6	-27.9	6.3	-21.7	-4.2	2.1	-25.9	n.m.	n.m.	n.m.	n.m.	-26.7%	n.m.	n.m.	>1.000%
EBITDA pre	589.6	703.6		685.4		564.5	1.249.9	2.543.1	708.0	719.8	1.427.8	835.7	2.263.5	731.2	1.566.9	2.994.6	20.1%	2.3%	10.4%	21.9%	14.4%	29.5%	25.4%	17.8%

Detailed reconciliation - Healthcare																								
€ million	Q1	Q2	H1	202 Q3	3 9M	Q4	H2	FY	Q1	Q2	H1	2024 Q3	9М	Q4	H2	FY	Q1	Q2	H1	Change Q3	YoY 9M	Q4	H2	FY
EBIT		245.0	4 405 5	250.0	4 700 7	405.0	4 000 4	2.224.6	242.2		4 440 0		4 000 =			100.0	18.9%	40.70/	-1.5%	40.00/	4.00/	42.2%	05.00/	11.5%
	519.7	615.8	1,135.5	653.2	1,788.7	435.9	1,089.1		618.0	500.9	1,118.9		1,860.7		1,361.7 2,			-10.7%		13.6%	4.0%	42.2% 15.0%	25.0%	
Regular depreciation and amortization*	71.9	70.4	142.3	68.5	210.9	76.7 11.8	145.3 11.8	287.6 16.0	77.7	81.0 10.6	158.7 19.6	77.4	236.2	88.2 20.9	165.6 29.4	324.4 49.1	8.0% >1.000%	15.1% 153.4%	11.5% 367.0%	13.0% >1.000%	12.0% 569.6%	77.5%	14.0% 149.8%	12.8% 207.0%
Impairments not adjusted Amortization of purchased intangible assets	0.0 1.5	4.2 1.6	4.2 3.2	0.0 1.7	4.2	1.7	3.3	6.5	9.0	1.6	3.2	8.5 1.6	4.8	1.5	3.1	6.4	3.7%	-0.9%	1.3%	-4.1%	-0.6%	-7.1%	-5.6%	-2.2%
	-0.6	0.0	-0.6			10.5	10.5	9.9			155.3						-100.0%					-7.1% -53.5%		-2.2% >1.000%
Impairments (net)**				0.0	-0.6			320.0	0.0	155.3		0.0	155.3 424.4	4.9	_	160.1	21.1%	n.m. 226.0%	n.m.	n.m. 24.7%	n.m. 93.5%	-53.5% 14.8%		
Total depreciation and amortization	72.9	76.2	149.1	70.2	219.4	100.6	170.9		88.3	248.5	336.8	87.6		115.5		539.9			125.9%				18.9%	68.7%
EBITDA	592.6	692.0	1,284.6	723.4	2,008.1	536.5	1,259.9	2,544.6	706.3	749.4	1,455.7	829.4	2,285.1	/35.4 1	1,564.8 3,	020.5	19.2%	8.3%	13.3%	14.6%	13.8%	37.1%	24.2%	18.7%
Adjustments																								
Acquisition costs	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Restructuring costs																								
Restructuring costs	-7.3	12.0	4.7	2.6	7.3	24.2	26.8	31.6	5.3	2.3	7.6	3.1	10.7	-2.6	0.5	8.1	n.m.	-81.2%	60.9%	19.5%	46.2%	n.m.	-98.1%	-74.4%
Total	-7.3	12.0	4.7	2.6	7.3	24.2	26.8	31.6	5.3	2.3	7.6	3.1	10.7	-2.6	0.5	8.1	n.m.	-81.2%	60.9%	19.5%	46.2%	n.m.	-98.1%	-74.4%
Integration costs/IT costs																								
Integration Cost	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
ERP/HR systems	4.0	3.5	7.4	5.1	12.5	7.2	12.3	19.7	1.1	2.7	3.8	3.1	6.9	4.3	7.4	11.2	-72.0%	-23.1%	-49.1%	-38.1%	-44.7%	-40.5%	-39.5%	-43.1%
Total	4.0	3.5	7.4	5.1	12.5	7.2	12.3	19.7	1.1	2.7	3.8	3.1	6.9	4.3	7.4	11.2	-72.0%	-23.1%	-49.1%	-38.1%	-44.7%	-40.5%	-39.5%	-43.1%
Gain (-)/ losses (+) on the divestment of bu	sinesses																							
Sale of Kuvan and Biosimilars	0.0	-7.6	-7.6	-50.5	-58.1	-4.0	-54.5	-62.1	-4.8	-28.7	-33.4	0.0	-33.4	-6.0	-6.0	-39.4	>1.000%	278.0%	339.7%	-100.0%	-42.4%	49.0%	-89.1%	-36.5%
Sale of Consumer Health	0.0	4.3	4.3	4.7	9.0	0.6	5.3	9.6	0.0	-5.9	-5.8	0.0	-5.8	0.0	0.1	-5.8	3.2%	n.m.	n.m.	-99.7%	n.m.	-92.8%	-99.0%	n.m.
Sale of Allergopharma	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Others	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Total	0.3	-3.9	-3.6	-45.8	-49.4	-3.4	-49.2	-52.8	-4.8	-34.5	-39.3	0.0	-39.3	-5.9	-5.9	-45.2	n.m.	786.9%	>1.000%	n.m.	-20.4%	72.0%	-88.0%	-14.4%
Other one-time costs																								
Others	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Total	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Total adjustments	-3.0	11.6	8.6	-38.1	-29.5	28.0	-10.1	-1.5	1.7	-29.6	-27.9	6.3	-21.7	-4.2	2.1	-25.9	n.m.	n.m.	n.m.	n.m.	-26.7%	n.m.	n.m.	>1.000%
EBITDA pre	589.6	703.6	1,293.2	685.4	1,978.5	564.5	1,249.9	2,543.1	708.0	719.8	1,427.8	835.7	2,263.5	731.2 1	1,566.9 2,	994.6	20.1%	2.3%	10.4%	21.9%	14.4%	29.5%	25.4%	17.8%

^{*} Regular depreciation and amortization = Depreciation and amortization - Amortization of purchased intangible assets - Impairments.

^{**} Only reflects impairments classified as adjustments.

Income Statement Merck KGaA, Darmstadt, Germany	y																							
Electronics		1		20	23								024							Change				
€ million	Q1	Q2	H1	Q3	9М	Q4	H2	FY	Q1	Q2	H1	Q3	9М	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY
Net sales	900.7	899.3	1,800.0	915.9	2,715.9	943.2	1,859.1	3,659.2	928.4	957.4	1,885.8	923.0	2,808.8	976.5	1,899.5	3,785.3	3.1%	6.5%	4.8%	0.8%	3.4%	3.5%	2.2%	3.4%
Cost of sales	-525.8	-572.2	-1,097.9	-592.2	-1,690.1	-641.9	-1,234.1	-2,332.0	-580.1	-572.8	-1,153.0	-558.4	-1,711.4	-607.5	-1,165.9	-2,318.9	10.3%	0.1%	5.0%	-5.7%	1.3%	-5.4%	-5.5%	-0.6%
thereof amortization of intangible assets	-33.6	-31.5	-65.2	-30.9	-96.1	-30.3	-61.2	-126.4	-30.0	-25.0	-55.0	-21.9	-76.9	-18.6	-40.5	-95.5	-10.8%	-20.6%	-15.6%	-29.2%	-20.0%	-38.4%	-33.8%	-24.4%
Gross profit	374.9	327.2	702.1	323.7	1,025.8	301.3	625.0	1,327.2	348.3	384.6	732.8	364.5	1,097.4	369.0	733.6	1,466.4	-7.1%	17.5%	4.4%	12.6%	7.0%	22.5%	17.4%	10.5%
in % of net sales	41.6%	36.4%	39.0%	35.3%	37.8%	31.9%	33.6%	36.3%	37.5%	40.2%	38.9%	39.5%	39.1%	37.8%	38.6%	38.7%								
SG&A	-215.1	-142.5	-357.7	-196.7	-554.3	-227.9	-424.6	-782.2	-180.0	-202.5	-382.5	-195.3	-577.8	-231.9	-427.2	-809.7	-16.3%	42.1%	6.9%	-0.7%	4.2%	1.8%	0.6%	3.5%
in % of net sales	23.9%	15.8%	19.9%	21.5%	20.4%	24.2%	22.8%	21.4%	19.4%	21.2%	20.3%	21.2%	20.6%	23.7%	22.5%	21.4%								
Marketing and selling expenses	-158.2	-147.6	-305.8	-143.7	-449.5	-141.3	-285.0	-590.8	-137.7	-141.9	-279.6	-140.5	-420.0	-147.7	-288.1	-567.7	-12.9%	-3.9%	-8.6%	-2.3%	-6.6%	4.6%	1.1%	-3.9%
thereof amortization of intangible assets (M&S)	-49.5	-48.2	-97.6	-48.1	-145.8	-49.3	-97.4	-195.0	-45.6	-45.5	-91.1	-44.5	-135.5	-45.4	-89.9	-181.0	-7.9%	-5.6%	-6.7%	-7.6%	-7.0%	-7.8%	-7.7%	-7.2%
Administration expenses	-33.0	-35.1	-68.1	-40.0	-108.0	-39.1	-79.1	-147.1	-37.2	-35.6	-72.8	-43.4	-116.2	-49.3	-92.7	-165.5	12.8%	1.6%	7.0%	8.5%	7.5%	26.1%	17.2%	12.5%
Impairment losses and reversals (IFRS 9)	-0.1	-0.1	-0.2	0.1	-0.1	0.0	0.1	-0.1	0.1	-1.4	-1.3	0.1	-1.3	-0.7	-0.7	-2.0	n.m.	>1.000%	535.6%	-34.2%	>1.000%	>1.000%	n.m.	>1.000%
Other operating expenses/income	-23.8	40.2	16.4	-13.1	3.3	-47.5	-60.6	-44.2	-5.2	-23.6	-28.8	-11.6	-40.3	-34.2	-45.7	-74.5	-78.3%	n.m.	n.m.	-11.3%	n.m.	-28.1%	-24.5%	68.7%
Impairments**	-10.3	-5.0	-15.3	-3.7	-18.9	-23.3	-27.0	-42.3	-0.5	-10.5	-11.0	-1.7	-12.7	-16.2	-17.9	-28.9	-95.3%	111.7%	-27.9%	-53.7%	-32.9%	-30.5%	-33.7%	-31.6%
Research and development costs	-74.1	-74.5	-148.7	-74.7	-223.4	-74.0	-148.7	-297.4	-73.1	-75.2	-148.2	-73.7	-221.9	-75.0	-148.7	-296.9	-1.5%	0.9%	-0.3%	-1.5%	-0.7%	1.4%	0.0%	-0.2%
in % of net sales	8.2%	8.3%	8.3%	8.2%	8.2%	7.8%	8.0%	8.1%	7.9%	7.9%	7.9%	8.0%	7.9%	7.7%	7.8%	7.8%								
thereof amortization of intangible assets (R&D)	-1.0	-0.9	-1.9	-1.0	-3.0	-1.2	-2.3	-4.2	-1.1	-1.2	-2.3	-1.2	-3.5	-2.9	-4.1	-6.4	19.5%	21.6%	20.5%	10.2%	16.9%	137.1%	78.6%	52.0%
EBIT	85.7	110.1	195.8	52.3	248.1	-0.5	51.7	247.5	95.2	106.9	202.1	95.5	297.6	62.1	157.6	359.7	11.1%	-2.9%	3.2%	82.8%	20.0%	n.m.	204.7%	45.3%
in % of net sales	9.5%	12.2%	10.9%	5.7%	9.1%	-0.1%	2.8%	6.8%	10.3%	11.2%	10.7%	10.4%	10.6%	6.4%	8.3%	9.5%								
Depreciation and amortization	142.6	134.7	277.3	133.5	410.8	157.4	290.9	568.2	129.8	135.2	265.0	122.8	387.8	139.1	261.9	526.9	-9.0%	0.4%	-4.4%	-8.0%	-5.6%	-11.6%	-10.0%	-7.3%
EBITDA	228.2	244.8	473.1	185.8	658.8	156.9	342.6	815.7	224.9	242.1	467.0	218.4	685.4	201.2	419.6	886.6	-1.4%	-1.1%	-1.3%	17.5%	4.0%	28.3%	22.5%	8.7%
in % of net sales	25.3%	27.2%	26.3%	20.3%	24.3%	16.6%	18.4%	22.3%	24.2%	25.3%	24.8%	23.7%	24.4%	20.6%	22.1%	23.4%								
EBITDA pre	237.3	261.7	499.1	207.9	707.0	206.0	413.9	913.0	236.6	255.3	491.9	235.2	727.1	242.5	477.7	969.6	-0.3%	-2.5%	-1.4%	13.2%	2.9%	17.7%	15.4%	6.2%
in % of net sales	26.4%	29.1%	27.7%	22.7%	26.0%	21.8%	22.3%	25.0%	25.5%	26.7%	26.1%	25.5%	25.9%	24.8%	25.2%	25.6%								
Parameter A. FRITPA																								
Reconciliation to EBITDA pre						4500	0.40.0	0453								222.2	4 40/	4.40/	4.00/	47.50/	4.00/	00.00/	00.5%	0.70/
EBITDA	228.2	244.8	473.1	185.8	658.8	156.9	342.6	815.7	224.9	242.1	467.0	218.4	685.4	201.2	419.6	886.6	-1.4%	-1.1%	-1.3%	17.5%	4.0%	28.3%	22.5%	8.7%
Adjustments																	50.007	04.00′	0.5%	00.001	40.401	07.00	74.40	F0.05'
thereof: Cost of Sales	2.0	5.9	8.0	7.3	15.3	21.8	29.1	37.1	3.2	4.5	7.7	1.4	9.1	7.0	8.4	16.1	58.2%	-24.8%	-3.5%	-80.9%	-40.4%	-67.9%	-71.1%	-56.6%
thereof: Marketing and selling expenses	0.0	0.5	0.5	2.0	2.5	8.0	2.8	3.3	0.1	0.3	0.4	-0.6	-0.1	2.3	1.8	2.2	>1.000%	-37.7%	-13.9%	n.m.	n.m.	198.3%	-35.5%	-32.3%
thereof: Administration expenses	2.0	3.6	5.7	7.7	13.3	15.4	23.1	28.7	4.7	1.7	6.5	11.1	17.6	15.2	26.3	32.8	135.0%	-52.8%	14.3%	45.0%	32.0%	-1.0%	14.3%	14.3%
thereof: Other operating expenses/income	5.1	6.4	11.5	4.9	16.4	11.0	16.0	27.5	3.4	6.5	9.9	5.0	14.9	16.2	21.1	31.0	-33.7%	1.9%	-14.0%	0.4%	-9.6%	46.5%	32.3%	12.9%
thereof: Research and development	-0.1	0.5	0.4	0.3	0.7	0.1	0.4	0.8	0.2	0.2	0.4	0.0	0.4	0.5	0.5	0.9	n.m.	-60.9%	-1.2%	n.m.	-45.3%	411.2%	31.3%	14.7%
Total	9.1	16.9	26.0	22.1	48.1	49.2	71.3	97.3	11.7	13.2	24.9	16.9	41.7	41.3	58.2	83.0	28.3%	-22.1%	-4.4%	-23.7%	-13.3%	-16.0%	-18.4%	-14.7%
EBITDA pre	237.3	261.7	499.1	207.9	707.0	206.0	413.9	913.0	236.6	255.3	491.9	235.2	727.1	242.5	477.7	969.6	-0.3%	-2.5%	-1.4%	13.2%	2.9%	17.7%	15.4%	6.2%

^{**} Only reflects impairments classified as adjustments.

Detailed reconciliation - Electronics																								
€ million	Q1	02	H1	20 Q3	23 aml	04	H2	FY	01	02	ыıİ	202 Q3	4 ом	04	H2	EV	Q1	02	⊔аТ	Chang Q3	e YoY ам	04	H2	FY
€ IIIIIIOII	QI	QZ	пп	હડ	SIVI	Q4	П	FI	QI	QZ	[11]	હુર	SIVI	Q4	ПΖ	FI	QI	QZ	111	વડ	SIVI	Q4	П	ГТ
EBIT	85.7	110.1	195.8	52.3	248.1	-0.5	51.7	247.5	95.2	106.9	202.1	95.5	297.6	62.1	157.6	359.7	11.1%	-2.9%	3.2%	82.8%	20.0%	n.m.	204.7%	45.3%
Regular depreciation and amortization*	48.2	49.1	97.3	49.7	147.0	53.3	103.0	200.3	52.3	53.0	105.3	53.4	158.7	56.2	109.6	214.9	8.6%	8.0%	8.3%	7.4%	8.0%	5.4%	6.3%	7.3%
Impairments not adjusted	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.2	0.2	0.4	-0.2	0.0	0.2	>1.000%	n.m. >	1.000% >	·1.000% [;]	1.000%	n.m.	n.m.	>1.000%
Amortization of purchased intangible assets	84.1	80.6	164.7	80.1	244.8	80.8	160.8	325.6	76.8	71.7	148.4	67.5	215.9	66.9	134.5	282.9	-8.7%	-11.1%	-9.9%	-15.7%	-11.8%	-17.1%	-16.4%	-13.1%
Impairments (net)**	10.3	5.0	15.3	3.7	18.9	23.3	27.0	42.3	0.5	10.5	11.0	1.7	12.7	16.2	17.9	28.9	- 95.3%	111.7%	-27.9%	-53.7%	-32.9%	-30.5%	-33.7%	-31.6%
Total depreciation and amortization	142.6	134.7	277.3	133.5	410.8	157.4	290.9	568.2	129.8	135.2	265.0	122.8	387.8	139.1	261.9	526.9	-9.0%	0.4%	-4.4%	-8.0%	-5.6%	-11.6%	-10.0%	-7.3%
EBITDA	228.2	244.8	473.1	185.8	658.8	156.9	342.6	815.7	224.9	242.1	467.0	218.4	685.4	201.2	419.6	886.6	-1.4%	-1.1%	-1.3%	17.5%	4.0%	28.3%	22.5%	8.7%
Adjustments																								
Acquisition costs	4.2	5.1	9.2	3.7	12.9	0.0	3.6	12.9	1.4	0.8	2.2	2.0	4.3	7.8	9.9	12.1	-65.8%	-84.1%	-75.9%	-44.5%	-67.0%	n.m.	170.6%	-6.1%
Restructuring costs																								
Restructuring costs	2.2	6.9	9.1	9.9	18.9	41.0	50.9	60.0	4.1	4.2	8.3	7.8	16.1	5.9	13.7	22.0	88.8%	-39.4%	-8.9%	-20.7%	-15.1%	-85.6%	-73.0%	-63.3%
Total	2.2	6.9	9.1	9.9	18.9	41.0	50.9	60.0	4.1	4.2	8.3	7.8	16.1	5.9	13.7	22.0	88.8%	-39.4%	-8.9%	-20.7%	-15.1%	-85.6%	-73.0%	-63.3%
Integration costs/IT costs																								
Integration Cost	1.1	1.0	2.1	1.2	3.3	0.5	1.6	3.8	1.1	1.4	2.6	-1.5	1.0	4.5	2.9	5.5	1.2%	38.3%	18.8%		-68.7%	852.2%	79.5%	45.1%
ERP/HR systems	1.7	3.9	5.6	7.4	13.0	7.7	15.1	20.7	5.1	5.4	10.4	8.5	19.0	7.9	16.5	26.9	203.6%	38.1%	87.8%	14.8%	46.0%	3.2%	8.9%	30.1%
Total	2.8	4.9	7.7	8.6	16.3	8.2	16.8	24.5	6.2	6.8	13.0	7.0	20.0	12.4	19.4	32.4	121.9%	38.2%	68.6%	-18.4%	22.7%	51.9%	15.8%	32.4%
Gain (-)/ losses (+) on the divestment of bus	sinesses																							
Costs related to former business activities	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.4	1.4	0.0	1.4	15.2	15.2	16.5	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Total	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.4	1.4	0.0	1.4	15.2	15.2	16.5	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Other one-time costs																								
Others	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Total	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Total adjustments	9.1	16.9	26.0	22.1	48.1	49.2	71.3	97.3	11.7	13.2	24.9	16.9	41.7	41.3	58.2	83.0	28.3%	-22.1%	-4.4%	-23.7%	-13.3%	-16.0%	-18.4%	-14.7%
EBITDA pre	237.3	261.7	499.1	207.9	707.0	206.0	413.9	913.0	236.6	255.3	491.9	235.2	727.1	242.5	477.7	969.6	-0.3%	-2.5%	-1.4%	13.2%	2.9%	17.7%	15.4%	6.2%

^{*} Regular depreciation and amortization = Depreciation and amortization - Amortization of purchased intangible assets - Impairments.

^{**} Only reflects impairments classified as adjustments.

Income Statement Merck KGaA, Darmstadt, Germany																								
Corporate and Other				202	3							202								Change				
€ million	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY
Net sales	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Cost of sales	-0.9	-2.6	-3.5	1.6	-1.9	-1.4	0.3	-3.2	0.3	1.4	1.7	0.5	2.2	-3.6	-3.1	-1.4	n.m.	n.m.	n.m.	-70.4%	n.m.	163.0%	n.m.	-57.1%
thereof amortization of intangible assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Gross profit	-0.9	-2.6	-3.5	1.6	-1.9	-1.4	0.3	-3.2	0.3	1.4	1.7	0.5	2.2	-3.6	-3.1	-1.4	n.m.	n.m.	n.m.	-70.4%	n.m.	163.0%	n.m.	-57.1%
SG&A	-217.8	-183.9	-401.7	-95.4	-497.1	-118.3	-213.6	-615.3	-145.0	-156.7	-301.8	-123.4	-425.2	-183.7	-307.1	-608.9	-33.4%	-14.8%	-24.9%	29.4%	-14.5%	55.3%	43.7%	-1.1%
Marketing and selling expenses	-2.8	-3.1	-5.9	0.5	-5.4	-1.9	-1.4	-7.3	-0.5	-0.1	-0.6	-1.1	-1.8	-15.9	-17.0	-17.7	-81.0%	-96.8%	-89.2%	n.m.	-67.4%	738.9% >	1.000%	143.0%
thereof amortization of intangible assets (M&S)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.2%	>1.000%	>1.000%	·1.000% ·	1.000%	1.000% >	1.000%	> 1.000%
Administration expenses	-144.4	-127.9	-272.3	-90.5	-362.8	-143.4	-233.9	-506.2	-107.4	-117.7	-225.1	-88.8	-313.8	-136.6	-225.3	-450.4	-25.6%	-8.0%	-17.3%	-1.9%	-13.5%	-4.8%	-3.7%	-11.0%
Impairment losses and reversals (IFRS 9)	0.0	0.0	0.0	0.0	0.0	-7.6	-7.6	-7.6	0.0	-0.2	-0.2	-0.4	-0.6	-1.3	-1.7	-1.9	-80.5%	n.m.	n.m.	n.m.	n.m.	-83.3%	-77.9%	-75.4%
Other operating expenses/income	-70.6	-52.9	-123.5	-5.4	-128.9	34.6	29.2	-94.3	-37.2	-38.7	-75.9	-33.1	-109.0	-29.9	-63.0	-138.9	-47.4%	-26.8%	-38.6%	508.7%	-15.5%	n.m.	n.m.	47.3%
Impairments**	0.0	0.0	0.0	-0.1	-0.1	-1.2	-1.3	-1.3	0.0	-0.5	-0.5	-0.2	-0.6	-2.0	-2.1	-2.6	n.m.	n.m.	n.m.	48.2%	503.8%	60.1%	59.2%	94.2%
Research and development costs	-24.1	-25.3	-49.4	-24.7	-74.0	-20.4	-45.1	-94.4	-14.6	-30.3	-45.0	-28.2	-73.1	-18.7	-46.9	-91.9	-39.3%	19.9%	-8.9%	14.2%	-1.2%	-8.2%	4.1%	-2.7%
thereof amortization of intangible assets (R&D)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
EBIT	-242.8	-211.7	-454.5	-118.4	-572.9	-140.0	-258.5	-713.0	-159.3	-185.7	-345.0	-151.1	-496.1	-205.9	-357.1	-702.1	-34.4%	-12.3%	-24.1%	27.6%	-13.4%	47.1%	38.2%	-1.5%
Depreciation and amortization	28.4	28.2	56.6	26.9	83.5	26.7	53.6	110.2	28.1	27.9	55.9	29.2	85.1	33.4	62.6	118.5	-1.2%	-1.1%	-1.2%	8.4%	1.9%	25.4%	16.9%	7.6%
EBITDA	-214.4	-183.5	-397.9	-91.5	-489.4	-113.4	-204.9	-602.8	-131.3	-157.8	-289.1	-121.9	-411.0	-172.5	-294.5	-583.5	-38.8%	-14.0%	-27.4%	33.3%	-16.0%	52.1%	43.7%	-3.2%
EBITDA pre	-140.5	-123.9	-264.5	-62.7	-327.2	-69.5	-132.3	-396.7	-101.9	-120.8	-222.8	-99.6	-322.4	-159.4	-259.1	-481.8	-27.5%	-2.5%	-15.8%	58.8%	-1.5%	129.3%	95.9%	21.4%
Reconciliation to EBITDA pre																								
EBITDA	-214.4	-183.5	-397.9	-91.5	-489.4	-113.4	-204.9	-602.8	-131.3	-157.8	-289.1	-121.9	-411.0	-172.5	-294.5	-583.5	-38.8%	-14.0%	-27.4%	33.3%	-16.0%	52.1%	43.7%	-3.2%
Adjustments																								
thereof: Cost of Sales	0.2	0.4	0.6	0.0	0.7	-0.1	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-100.0%	-99.7%	-99.8%	-34.9%	-96.9%	######	n.m.	-96.6%
thereof: Marketing and selling expenses	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.1	-0.1	0.0	0.1	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
thereof: Administration expenses	54.6	22.8	77.5	12.2	89.6	54.5	66.7	144.2	20.0	17.1	37.1	10.4	47.5	3.5	13.9	51.0	-63.4%	-25.1%	-52.1%	-14.9%	-47.0%	-93.5%	-79.2%	-64.6%
thereof: Other operating expenses/income	19.0	35.0	54.0	16.6	70.6	-10.5	6.1	60.1	9.6	19.7	29.3	11.9	41.2	9.6	21.5	50.8	-49.8%	-43.7%	-45.8%	-28.0%	-41.6%	n.m.	254.0%	-15.5%
thereof: Research and development	0.0	1.3	1.3	0.0	1.3	-0.2	-0.1	1.2	-0.2	0.0	-0.2	0.0	-0.2	0.0	0.0	-0.2	n.m.	-97.5%	n.m.	######	n.m.	######	######	n.m.
Total	73.9	59.6	133.5	28.8	162.2	43.9	72.6	206.1	29.4	37.0	66.3	22.3	88.6	13.1	35.4	101.7	-60.3%	-37.9%	-50.3%	-22.5%	-45.4%	-70.2%	-51.3%	-50.6%
EBITDA pre	-140.5	-123.9	-264.5	-62.7	-327.2	-69.5	-132.3	-396.7	-101.9	-120.8	-222.8	-99.6	-322.4	-159.4	-259.1	-481.8	-27.5%	-2.5%	-15.8%	58.8%	-1.5%	129.3%	95.9%	21.4%

Due to rounding the sum of individual values may not add up to totals presented.
** Only reflects impairments classified as adjustments.

Detailed reconciliation -	Corporate	and Others
---------------------------	-----------	------------

				202	3							2024	4							Chang	e YoY			
€ million	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY
EBIT	-242.8	-211.7	-454.5	-118.4	-572.9	-140.0	-258.5	-713.0	-159.3	-185.7	-345.0	-151.1	-496.1	-205.9	-357.1 -	702.1	-34.4%	-12.3%	-24.1%	27.6%	-13.4%	47.1%	38.2%	-1.5%
Regular depreciation and amortization*	28.4	28.2	56.6	26.8	83.4	25.4	52.2	108.8	28.1	27.4	55.5	29.2	84.6	31.3	60.5	115.9	-1.2%	-2.9%	-2.0%	8.8%	1.4%	23.2%	15.8%	6.5%
Impairments not adjusted	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-0.2	-0.2	0.1	0.0	0.0	n.m.	n.m.	n.m.	n.m.	n.m.		>1.000%	
Amortization of purchased intangible assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.2%	>1.000%	1.000%			>1.000%		
Impairments (net)**	0.0	0.0	0.0	0.1	0.1	1.2	1.3	1.3	0.0	0.5	0.5	0.2	0.6	2.0	2.1	2.6	n.m.	n.m.	n.m.	48.2%	503.8%	60.1%	59.2%	94.2%
Total depreciation and amortization	28.4	28.2	56.6	26.9	83.5	26.7	53.6	110.2	28.1	27.9	55.9	29.2	85.1	33.4	62.6	118.5	-1.2%	-1.1%	-1.2%	8.4%	1.9%	25.4%		7.6%
EBITDA	-214.4	-183.5	-397.9	-91.5	-489.4	-113.4	-204.9	-602.8	-131.3	-157.8	-289.1	-121.9	-411.0	-172.5	-294.5 -	583.5	-38.8%	-14.0%	-27.4%	33.3%	-16.0%	52.1%	43.7%	-3.2%
Adjustments																								
Acquisition costs	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Restructuring costs															_									
Restructuring costs	49.0	18.5	67.6	7.9	75.4	52.0	59.8	127.4	17.2	19.1	36.3	12.0	48.2	-8.1	3.8	40.1	-65.0%	2.9%	-46.4%	52.3%	-36.1%			
Total	49.0	18.5	67.6	7.9	75.4	52.0	59.8	127.4	17.2	19.1	36.3	12.0	48.2	-8.1	3.8	40.1	-65.0%	2.9%	-46.4%	52.3%	-36.1%	n.m.	-93.6%	-68.5%
IT project costs																								
Integration Cost	0.0	0.1	0.1	0.1	0.2	0.1	0.2	0.3	0.1	0.1	0.2	0.0	0.2	0.0	0.0	0.2	82.1%	41.0%	60.1%	-55.4%	21.2%	n.m.	n.m.	-38.4%
ERP/HR systems	5.6	6.8	12.4	4.9	17.3	3.6	8.5	20.9	2.7	3.9	6.6	3.7	10.4	2.1	5.8	12.5	-51.1%	-42.7%	-46.5%		-40.2%	-41.5%	-31.6%	-40.4%
Total	5.6	6.9	12.5	5.0	17.5	3.7	8.7	21.2	2.8	4.0	6.8	3.8	10.6	2.1	5.8	12.6	-49.9%	-42.0%	-45.6%	-24.7%	-39.6%	-44.0%	-32.9%	-40.4%
Gain (-)/ losses (+) on the divestment of busi	nesses																							
Costs related to former business activities	0.0	21.0	21.0	-3.0	18.0	-16.6	-19.6	1.4	0.0	-18.6	-18.6	0.0	-18.6	0.0	0.0	-18.6	n.m.	n.m.	n.m.	######	n.m.			n.m.
Total	0.0	21.0	21.0	-3.0	18.0	-16.6	-19.6	1.4	0.0	-18.6	-18.6	0.0	-18.6	0.0	0.0	-18.6	n.m.	n.m.	n.m.	######	n.m.	######	######	n.m.
Other one-time costs																								
Others	19.2	13.2	32.4	18.9	51.3	4.8	23.7	56.1	9.4	32.5	41.9	6.6	48.5	19.1	25.7	67.6	-51.2%	146.4%	29.3%		-5.5%	296.8%		20.4%
Total	19.2	13.2	32.4	18.9	51.3	4.8	23.7	56.1	9.4	32.5	41.9	6.6	48.5	19.1	25.7	67.6	-51.2%	146.4%	29.3%	-65.2%	-5.5%	296.8%	8.3%	20.4%
Total adjustments	73.9	59.6	133.5	28.8	162.2	43.9	72.6	206.1	29.4	37.0	66.3	22.3	88.6	13.1	35.4	101.7	-60.3%	-37.9%	-50.3%	-22.5%	-45.4%	-70.2%	-51.3%	-50.6%
EBITDA pre	-140.5	-123.9	-264.5	-62.7	-327.2	-69.5	-132.3	-396.7	-101.9	-120.8	-222.8	-99.6	-322.4	-159.4	-259.1 -	481.8	-27.5%	-2.5%	-15.8%	58.8%	-1.5%	129.3%	95.9%	21.4%

^{*} Regular depreciation and amortization = Depreciation and amortization - Amortization of purchased intangible assets - Impairments.

^{**} Only reflects impairments classified as adjustments.

Income Statement Merck KGaA, Darmstadt, Germany

Group € million	Q1	Q2	2023 H1	Q3	9М	04	H2	FY	01	Q2	H1	202 Q3	24 9M	Q4	на	FY	Q1 Q2	Change YoY H1 Q3 9M Q4 H2 FY
CHIMION	ه ۱	مدا		ام	5141	الم	1121		۱۱ ۳	مدا		QU	OWI	٩٠١	1121		م، ا هدا	111 00 0111 04 112 11
Financial result	-22.7	-75.7	-98.4	-46.0	-144.3	19.1	-26.8	-125.2	-32.2	-7.2	-39.4	-54.1	-93.5	-15.0	-69.1	-108.5	42.1% -90.6%	-60.0% 17.7% -35.2% n.m. 157.6% -13.4%
Interest result	-27.4	-48.7	-76.1	-39.2	-115.3	15.3	-23.8	-100.0	-22.1	-7.5	-29.6	-21.8	-51.4	-8.9	-30.7	-60.3	-19.4% -84.7%	-61.2% -44.3% -55.4% n.m. 29.0% -39.7%
Interest income	20.6	36.7	57.3	25.0	82.2	70.8	95.8	153.0	28.1	45.3	73.4	37.2	110.6	53.6	90.8	164.2	36.4% 23.6%	28.2% 49.1% 34.5% -24.3% -5.2% 7.3%
Interest expenses	-48.0	-85.4	-133.4	-64.1	-197.5	-55.4	-119.6	-253.0	-50.1	-52.8	-103.0	-59.1	-162.0	-62.5	-121.6	-224.5	4.5% -38.2%	-22.8% -7.9% -18.0% 12.8% 1.6% -11.2%
Result from financial investments	13.4	7.4	20.8	12.7	33.5	10.6	23.2	44.1	7.3	11.1	18.3	-19.0	-0.7	2.6	-16.4	1.9	-46.0% 50.3%	-11.9% n.m. n.m75.2% n.m95.6%
Currency difference - financing	-1.4	-4.8	-6.3	5.6	-0.6	-0.4	5.3	-1.0	6.4	8.0	14.3	1.5	15.8	11.8	13.3	27.6	n.m. n.m.	n.m73.1% n.m. n.m. 151.3% n.m.
Interest quota - pensions and other provis	-7.3	-29.5	-36.8	-25.1	-61.9	-6.4	-31.5	-68.3	-23.8	-18.7	-42.5	-14.7	-57.2	-20.4	-35.2	-77.7	227.0% -36.7%	15.4% -41.3% -7.6% 219.1% 11.7% 13.7%
Others	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-73.3% 700.0%	n.m. n.m. n.m. 75.6% 75.6% 75.6%

Cash Flow Statement Merck KGaA. Darmstadt. Germany																								
Group				20	23							202	4							Change	VoV			
€ million	Q1	02		03	oM	Q4	Hal	FV	Q1	Q2		03	oMI	04	Hal	FY	Q1	Q2		Q3	IMP	Q4	Hal	FV
Profit after tax	799.7	706.1	1.505.8	740.4	2.246.2	587.6	1.328.0	2.833.8	699.5	605.4	1.304.9	811.7	2.116.5	669.3	1.480.9	2.785.8	-12.5%	-14.3%	-13.3%	9.6%	-5.8%	13.9%	11.5%	-1.7%
Depreciation/amortization/impairment losses/reversals of impairment losses	455.5	482.3	937.8	435.2	1.373.0	506.7	941.9	1,879.7	453.5	680.1	1,133.6	449.3	1.582.9	550.8	1,000.1	2,703.8	-0.4%	41.0%	20.9%	3.2%	15.3%	8.7%	6.2%	13.5%
of tangible assets	216.6	216.7	433.3	224.3	657.6	259.6	483.9	917.2	231.5	286.1	517.5	242.6	760.2	306.3	549.0	1.066.5	6.9%	32.0%	19.4%	8.2%	15.6%	18.0%	13.5%	16.3%
of intangible assets	238.9	265.6	504.5	210.9	715.4	247.1	458.0	962.6	222.0	394.1	616.1	206.6	822.7	244.5	451.1	1.067.3	-7.1%	48.4%	22.1%	-2.0%	15.0%	-1.1%	1 50/	10.9%
Changes in working capital	-223.9	-52.9	-276.8	-35.2	-312.0	171.5	136.3	-140.5	-177.4	-133.7	-311.2	-13.1	-324.2	261.6	248.5	-62.6	-20.8%	153.0%	12.4%	-62.8%	3.9%	52.6%	82.4%	-55.4%
Changes in inventories	-322.5	-106.3	-428.9	91.8	-337.0	248.3	340.2	-88.7	-40.9	1.1	-39.8	4.0	-35.9	71.6	75.6	35.7	-87.3%	n.m.	-90.7%	-95.7%	-89.4%	-71.2%	-77.8%	n.m.
Changes in trade accounts receivable	-116.5	14.7	-101.8	51.8	-50.0	41.6	93.3	-8.5	-64.0	-109.5	-173.6	78.1	-95.5	174.6	252.7	79.1	-45.0%	n.m.	70.6%	50.9%	90.9%	320.2%	170.8%	n.m.
Changes in trade accounts receivable Changes in trade accounts payable/ refund liabilities	215.1	38.8	253.9	-178.8	75.1	-118.5	-297.2	-43.4	-72.5	-25.3	-97.7	-95.1	-192.9	15.4	-79.8	-177.5	n.m.	n.m.	n.m.	-46.8%	n.m.	n.m.	-73.2%	309.3%
Changes in trade accounts payable/ return nabilities Changes in provisions	-8.0	53.3	45.3	30.2	75.5	112.9	143.1	188.4	40.0	-18.3	21.7	19.2	40.9	21.3	40.6	62.3	n.m.	n.m.	-52.1%	-36.3%	-45.8%	-81.1%	-71.7%	-67.0%
Changes in provisions Changes in other assets and liabilities	-187.0	-421.0	-608.0	143.1	-464.9	-290.1	-147.1	-755.1	32.6	-264.8	-232.2	180.0	-52.3	-256.7	-76.7	-308.9		-37.1%	-61.8%	25.8%	-88.8%	-11.5%	-47.8%	-59.1%
Neutralization of gain/loss on disposal of fixed assets and other disposals	-107.0	-145.5	-145.7	-7.0	-464.9	2.4	-147.1	-150.3	-7.9	-204.0	-232.2 -9.2	0.0	-52.3 -9.2	-230.7 7.1	7.0	-306.9	n.m. >1.000%	-99.1%	-93.7%	-99.6%	-94.0%	192.7%	-47.070	-98.6%
Other non-cash income and expenses	16.5	0.1	16.7	-51.3	-34.6	-37.8	-89.1	-72.4	-5.0	-6.3	-11.3	11.3	0.0	-22.0	-10.7	-22.0	n.m.	n.m.	n.m.	n.m.	-99.9%	-41.8%	-88.0%	-69.6%
Operating Cash Flow	852.7	622.4	1.475.2	1.255.4	2.730.6	1.053.1	2.308.5	3.783.7	1.035.1	861.2	1.896.3	1.458.3	3.354.6	1.231.5	2.689.8	4.586.1	21.4%	38.4%	28.6%	16.2%	22.9%	16.9%	16.5%	21.2%
thereof: from discontinued operations	0.0	0.0	0.0	0.0	0.0	1,053.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0			20.0% n.m.					n.m.
thereor. Ironi discontinued operations	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.m.	n.m.	11.111.	n.m.	n.m.	n.m.	n.m.	m.m.
Payments for investments in intangible assets	-79.0	-30.9	-109.9	-33.7	-143.5	-72.6	-106.3	-216.2	-248.0	-34.9	-282.9	-97.7	-380.6	-100.9	-198.6	-481.5	214.0%	12.8%	157.4%	190.5%	165.2%	38.9%	86.9%	122.7%
Payments from the disposal of intangible assets	4.4	125.8	130.2	4.9	135.0	0.8	5.6	135.8	5.9	1.9	7.8	0.9	8.7	9.0	9.8	17.6	35.4%	-98.5%	-94.0%	-82.0%	-93.6%	>1.000%	74.8%	-87.0%
Payments for investments in property, plant and equipment	-572.3	-295.6	-867.9	-428.4	-1.296.3	-511.0	-939.4	-1.807.4	-522.8	-315.7	-838.5	-455.7	-1.294.2	-407.4	-863.1	-1.701.6	-8.6%	6.8%	-3.4%	6.4%	-0.2%	-20.3%	-8.1%	-5.8%
Payments from the disposal of property, plant and equipment	10.1	3.3	13.4	4.2	17.6	1.1	5.4	18.7	10.7	6.0	16.7	18.1	34.8	-8.2	10.0	26.6	5.8%	83.0%	24.6%	327.8%	97.5%	n.m.	85.6%	42.0%
Payments for acquisitions less acquired cash and cash equivalents (net)	0.1	0.1	0.1	-9.4	-9.3	-2.5	-11.9	-11.8	0.0	0.0	0.0	-553.9	-553.9	-219.9	-773.8	-773.8	-100.0%	-100.0%	-100.0%	>1.000%	>1.000%	>1.000%	>1.000%	>1.000%
Payments from divestments	-0.1	-0.2	-0.2	0.0	-0.2	0.0	0.0	-0.2	6.3	0.1	6.3	0.0	6.3	0.5	0.5	6.8	n.m.	n.m.	n.m.	>1.000%	n.m.	>1.000%	>1.000%	n.m.
Payments for investments in other assets ¹	-918.9	-1,119.3	-2.038.2	-358.8	-2.397.0	-634.4	-993.2	-3,031.4	-287.5	-42.3	-329.8	-1.503.9	-1.833.7	-417.3	-1.921.2	-2,251.0	-68.7%	-96.2%	-83.8%	319.1%	-23.5%	-34.2%	93.4%	-25.7%
Payments from the disposal of other assets ²	324.5	1.457.0	1.781.6	470.8	2,252.4	768.2	1.239.1	3,020.6	346.7	354.5	701.1	894.0	1.595.2	511.9	1,405.9	2.107.0	6.8%	-75.7%	-60.6%	89.9%	-29.2%	-33.4%	13.5%	-30.2%
Investing Cash Flow	-1.231.1	140.2	-1.091.0	-350.3	-1,441.3	-450.5	-800.8	-1,891.8	-688.7	-30.5	-719.2	-1,698.2	-2.417.4	-632.4	-2.330.6	-3.049.8	-44.1%	n.m.	-34.1%	384.7%	67.7%	40.4%	191.0%	61.2%
thereof: from discontinued operations	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n m	n.m.
androot. Horri diocontantica operatione	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	•••••							
Dividend payments to Merck KGaA shareholders	0.0	-284.3	-284.3	0.0	-284.3	0.0	0.0	-284.3	0.0	-284.3	-284.3	0.0	-284.3	0.0	0.0	-284.3	n.m.	0.0%	0.0%	n.m.	0.0%	n.m.	n.m.	0.0%
Dividend payments to non-controlling interests	0.0	-10.3	-10.3	-0.3	-10.6	-1.1	-1.4	-11.7	0.0	-9.1	-9.1	0.0	-9.1	0.0	0.0	-9.1	n.m.	-11.2%	-11.2%	-100.0%	-13.9%	n.m.	n.m.	-21.7%
Profit withdrawal by E.Merck KG	-90.4	-777.6	-868.0	0.0	-868.0	0.0	0.0	-868.0	-52.3	-694.3	-746.6	0.0	-746.6	0.0	0.0	-746.6	-42.1%	-10.7%	-14.0%	n.m.	-14.0%	n.m.	n.m.	-14.0%
Changes in financial liabilities to E. Merck KG and E. Merck Beteiligungen KG	-0.8	697.8	697.1	-100.0	597.1	-320.4	-420.4	276.7	-26.9	556.4	529.5	16.8	546.3	-315.7	-298.9	230.6	>1.000%	-20.3%	-24.0%	n.m.	-8.5%	-1.5%	-28.9%	-16.7%
Other changes in net equity	0.0	0.0	0.0	0.1	0.1	0.2	0.3	0.3	-0.1	0.0	-0.1	0.0	-0.1	0.5	0.5	0.5	>1.000%	>1.000%	n.m.	n.m.	n.m.	197.6%	96.2%	70.8%
Changes in current and non-current financial liabilities	215.6	-206.0	9.7	-202.2	-192.5	-652.7	-854.9	-845.3	-27.6	71.5	43.9	710.6	754.5	-930.6	-220.0	-176.2	n.m.	n.m.	354.4%	n.m.	n.m.	42.6%	-74.3%	-79.2%
Other changes from financing activities	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-0.1	-0.1	n.m.	n.m.	n.m.	n.m.	40.6%	n.m.	n.m.	523.8%
Financing Cash Flow	124.5	-580.4	-455.9	-302.4	-758.3	-974.0	-1,276.4	-1,732.3	-106.9	-359.8	-466.8	727.4	260.6	-1,245.8	-518.4	-985.2	n.m.	-38.0%	2.4%	n.m.	n.m.	27.9%	-59.4%	-43.1%
thereof: from discontinued operations	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Changes in cash and cash equivalents	-254.0	182.2	-71.7	602.7	530.9	-371.3	231.3	159.6	239.5	470.9	710.4	487.5	1.197.9	-646.8	-159.3	551.1	n.m.	158 4%	n.m.	-19.1%	125.6%	74.2%	n m	245.3%
Changes in cash and cash equivalents Changes in cash and cash equivalents due to currency translation	-15.7	-5.3	-21.1	1.7	-19.3	-12.1	-10.4	-31.4	-2.0	-5.4	-7.4	-11.5	-18.9	2.8	-8.8	-16.1	-87.5%	1.4%	-65.0%	n.m.	-2.3%	n.m.	-15 3%	-48.6%
Cash and cash equivalents as of January 1st	1.853.8	0.0	1.853.8	0.0	1.853.8	0.0	0.0	1,853.8	1.982.0	0.0	1.982.0	0.0	1.982.0	0.0	0.0	1.982.0	6.9%	n.m.	6.9%	n.m.	6.9%	n.m.	n.m.	6.9%
Cash and cash equivalents	1,584.1	176.9	1,761.0	604.4	2.365.4	-383.4	221.0	1,982.0	2.219.6	465.5	2.685.0	476.0	3.161.0	-644.0	-168.0	2.517.0	40.1%	163.1%	52.5%	-21.2%	33.6%	68.0%	n.m.	27.0%
Changes in cash and cash equivalents due to change in scope of consolidation		0.0	0.0	0.0	2,365.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2,517.0	40.1% n.m.	n.m.	n.m.	-21.2% n.m.	n.m.	n.m.	n.m.	n.m.
Changes in cash and cash equivalents due to change in scope of consolidation	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	11.111.	0.10.	(1.111.	11.111.	11.111.	11.111.	0.00.	11.111.

¹ The lines "Payments for investments in financial assets" and "Payments from disposal of non-financial assets", which were presented separately in the previous year, have been summarized to improve clarity and transparency.

² The lines "Proceeds from the disposal of other financial assets" and "Proceeds from the disposal of non-financial assets", which were presented separately in the previous year, have been summarized to improve clarity and transparency.

Due to rounding the sum of individual values may not add up to totals presented.

Company Comp
Non-current assests \$3,686.3 \$3,783.3 \$3,393.9 \$3,6102.3 \$3,680.9 \$3,622.3 \$3,611.1 73.4% 73.9% 72.9% 74.4% 73.9% 72.2% 73.9%
Conversion Con
Charmangable assets 6,953.8 6,765.2 6,716.5 6,551.3 6,406.6 6,208.0 5,246.1 14.3% 13.9% 13.5% 13.5% 13.5% 13.6% 11.8% 12.2% 11.9%
Property, plant and equipment 8,2179 8,3934 8,7192 9,0559 9,2144 9,4350 9,4147 10,0250 16,996 17,278 17,576 18,766 18,696 18,996 18,896 19,496 10,0060 0,0
Investments accounted for using the equity method 2.9 2.9 3.0 2.9 2.9 2.8 3.0 0.0%
Other non-current receivables 958,9 1,040,9 999,8 990,8 190,77 1,062,2 1,090,1 1,172,3 2,0% 2,1% 2,0% 2,0% 2,0% 2,0% 2,0% 2,0% 2,0% 2,0
Other non-current (financial assets
Other non-current non-financial assets
Non-current income tax receivables Deferred tax assets 1342.5 1,342.5
Deferred tax assets 1,342.5 1,338.2 1,315.1 1,514.3 1,560.4 1,632.8 1,805.8 1,312.0 2.8% 2.7% 2.6% 3.1% 3.2% 3.3% 3.2% 2.5% Current assets 12,950.7 13,018.7 13,566.4 12,393.2 12,823.5 13,046.6 13,928.6 13,450.4 26.6% 26.7% 27.2% 25.6% 25.9% 26.2% 27.8% 26.1% Inventories 4,899.6 4,995.8 4,971.1 4,633.9 4,116.4 4,714.4 4,604.8 4,484.2 10.1% 10.2% 10.0% 9.5% 9.5% 9.5% 8.8% 8.7% Contract assets 12,826.6 12,825.5 12.2.1 103.7 99.1 123.2 120.0 131.5 0.3% 0.3% 0.2% 0.2% 0.2% 0.2% 0.2% 0.2% 0.2% 0.2
Inventories 4,886,6 4,995,8 4,971,1 4,636,9 4,716,4 4,714,4 4,404,8 4,484,2 10,1% 10,2% 10,0% 9,6% 9,5% 9,5% 8,8% 8,7% Contract assets 132,6 126,5 122,1 103,7 99,1 123,2 120,0 131,5 0,3% 0,3% 0,3% 0,2% 0,2% 0,2% 0,2% 0,2% 0,2% 0,2% 0,2
Trade and other current receivables Contract assets 126.8 4,269.8 4,195.1 4,003.9 4,147.1 4,263.0 3,988.0 3,946.5 8.8% 8.6% 8.4% 8.3% 8.4% 8.5% 8.0% 7.7% Contract assets 136.8 126.5 122.1 103.7 99.1 123.2 120.0 131.5 0.3% 0.3% 0.2% 0.2% 0.2% 0.2% 0.2% 0.2% 0.2% 0.2
Contract assets Other current financial assets 1,515.8 1,250.0 1,140.2 632.5 942.4 672.5 622.0 621.2 3,1% 2,6% 2,3% 1,3% 1,9% 1,3% 1,2% Other current non-financial assets 1,515.8 1,250.0 1,140.2 632.5 942.4 672.5 622.0 621.2 3,1% 2,6% 2,3% 1,3% 1,9% 1,3% 1,2% 1,2% Current income tax receivables 0,421.9 509.2 554.2 472.8 434.8 456.9 355.8 511.7 0,9% 1,0% 1,1% 1,0% 0,9% 0,9% 0,7% 1,0% Assets held for sale 0,0 0,0 0,0 0,0 0,0 62.3 0,0 0,0 577.9 596.7 0,0% 0,0% 0,0% 0,0% 0,0% 0,0% 0,0% 0,0
Other current financial assets 136.8 166.3 218.3 499.1 264.1 129.7 699.2 641.6 0.3% 0.3% 0.4% 1.0% 0.5% 0.3% 1.4% 1.2% Other current financial assets 1,515.8 1,250.0 1,140.2 632.5 942.4 672.5 622.0 621.2 3.1% 2.6% 2.3% 1.3% 1.9% 0.9% 0.7% 1.0% Current income tax receivables 421.9 509.2 554.2 472.8 434.8 458.9 355.8 511.7 0.9% 1.0% 1.1% 1.0% 0.9% 0.7% 1.0% Cash and cash equivalents 1,584.1 1,761.0 2,365.4 1,982.0 2,219.6 2,685.0 3,161.0 2,517.0 3.3% 3.6% 4.7% 4.1% 4.5% 5.4% 6.3% 4.9% Assets held for sale 48,637.0 48,781.9 49,906.2 48,495.4 49,875.0 50,141.9 51,566.6 100.0% 100.0% 100.0% 100.0% 100.
Other current non-financial assets 1,515.8 1,250.0 1,140.2 632.5 942.4 672.5 622.0 621.2 3.1% 2.6% 2.3% 1.3% 1.9% 1.3% 1.2% 1.2% Current income tax receivables 421.9 509.2 554.2 472.8 434.8 458.9 355.8 511.7 0.9% 1.0% 1.1% 1.0% 0.9% 0.7% 1.0% Assets held for sale Cash and cash equivalents 1,584.1 1,584.1 1,584.1 1,584.1 1,982.0 2,219.6 2,219.6 2,2685.0 3,161.0 2,517.0 3.3% 3.6% 4.7% 4.1% 4.5% 5.4% 6.3% 4.9% Assets held for sale 0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Current income tax receivables 421.9 509.2 554.2 472.8 434.8 458.9 355.8 511.7 0.9% 1.0% 1.0% 1.0% 0.9% 0.9% 0.7% 1.0% Cash and cash equivalents 1,584.1 1,761.0 2,365.4 1,982.0 2,219.6 2,685.0 3,161.0 2,517.0 3.3% 3.6% 4.7% 4.1% 4.5% 5.4% 6.3% 4.9% Assets held for sale 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.
Cash and cash equivalents Assets held for sale 1,584.1 1,761.0 2,365.4 1,982.0 2,219.6 62.3 0.0 0.0 577.9 596.7 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.
Assets held for sale 0.0 0.0 0.0 62.3 0.0 0.0 577.9 596.7 0.0% 0.0% 0.0% 0.0% 0.1% 0.0% 0.0% 1.2% 1.2% Total assets 48,637.0 48,781.9 49,906.2 48,495.4 49,504.4 49,875.0 50,141.9 51,566.6 100.0%
Total equity 26,230.0 26,771.9 28,294.5 26,754.3 28,074.2 28,616.0 28,393.4 29,987.5 53.9% 54.9% 56.7% 55.2% 56.7% 57.4% 56.6% 58.2% Equity capital 565.2
Equity capital 565.2 565
Equity capital 565.2 565
Capital reserves 3,813.7 7.8% 7.8% 7.6% 7.9% 7.6%
Retained earnings 19,250.0 19,760.5 20,710.7 20,228.2 21,031.1 21,378.7 22,145.5 22,085.6 39.6% 40.5% 41.5% 41.7% 42.5% 42.9% 44.2% 42.8% Gain/losses recognized in equity 2,520.3 2,561.2 3,132.2 2,072.6 2,585.9 2,791.6 1,798.9 3,447.7 5.2% 5.3% 6.3% 4.3% 5.2% 5.6% 3.6% 6.7% Non-controlling interest 80.7 71.3 72.7 74.53 78.2 66.8 70.1 75.3 0.2% 0.1% 0.1% 0.2% 0.2% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1%
Gain/losses recognized in equity 2,520.3 2,561.2 3,132.2 2,072.6 2,585.9 2,791.6 1,798.9 3,447.7 5.2% 5.3% 6.3% 4.3% 5.2% 5.6% 3.6% 6.7% Non-controlling interest 80.7 71.3 72.7 74.53 78.2 66.8 70.1 75.3 0.2% 0.1% 0.1% 0.2% 0.2% 0.1% 0.1% 0.1% 0.1%
Non-controlling interest 80.7 71.3 72.7 74.53 78.2 66.8 70.1 75.3 0.2% 0.1% 0.1% 0.2% 0.2% 0.1% 0.1% 0.1% 0.1%
Non-current liabilities 12,850.8 13,163.9 12,926.3 13,041.7 11,491.1 11,327.6 11,286.0 10,284.9 26.4% 27.0% 25.9% 26.9% 23.2% 22.7% 22.5% 19.9%
Non-current provisions for employee benefits 1,965.3 1,994.5 1,773.6 2,192.0 2,132.9 2,064.2 2,068.0 1,955.7 4.0% 4.1% 3.6% 4.5% 4.3% 4.1% 4.1% 3.8%
Other non-current provisions 307.0 294.1 276.0 277.4 262.7 240.3 240.1 256.8 0.6% 0.6% 0.6% 0.6% 0.5% 0.5% 0.5% 0.5% 0.5%
Non-current financial debt 9,159.3 9,495.4 9,540.5 9,239.5 7,822.5 7,822.0 7,884.2 6,997.0 18.8% 19.5% 19.1% 19.1% 15.8% 15.7% 15.7% 13.6%
Other non-current financial liabilities 142.4 141.3 142.8 147.1 150.5 130.7 136.2 134.8 0.3% 0.3% 0.3% 0.3% 0.3% 0.3% 0.3% 0.3%
Other non-current non-financial liabilities 19.3 19.0 18.2 16.5 16.3 12.1 11.2 12.5 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.
Non-current income tax liabilities 38.0 37.5 41.0 39.5 39.4 39.5 39.2 36.41 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1
Current liabilities 9,556.2 8,846.1 8,689.4 9,939.1 9,931.4 10,462.5 11,294.2 19.6% 18.1% 17.4% 17.9% 20.1% 19.9% 20.9% 21.9%
Current provisions for employee benefits 131.6 105.9 124.4 82.9 81.3 73.0 71.2 65.6 0.3% 0.2% 0.2% 0.2% 0.2% 0.1% 0.1% 0.1%
Other current provisions 378.8 448.1 469.0 575.0 594.0 597.3 592.9 504.7 0.8% 0.9% 0.9% 1.2% 1.2% 1.2% 1.0%
Current financial debt 1,484.9 1,690.1 1,415.7 701.5 2,130.5 2,927.5 3,508.5 3,304.0 3.1% 3.5% 2.8% 1.4% 4.3% 5.9% 7.0% 6.4% Other current financial liabilities 1.017.3 259.1 241.8 1.005.1 994.4 276.3 199.1 1.030.4 2.1% 0.5% 0.5% 2.1% 2.0% 0.6% 0.4% 2.0%
Trade and other current payables 2,326.1 2,402.7 2,243.8 2,545.4 2,086.0 2,121.6 1,950.0 2,274.5 4.8% 4.9% 4.5% 5.2% 4.2% 4.3% 3.9% 4.4% Refund liabilities 947.1 963.1 990.0 876.8 880.9 890.5 853.5 868.9 1.9% 2.0% 2.0% 1.8% 1.8% 1.8% 1.7% 1.7%
Current income tax liabilities 1,461.4 1,487.8 1,580.7 1,433.4 1,564.9 1,659.7 1,672.7 1,527.5 3.0% 3.0% 3.2% 3.0% 3.2% 3.3% 3.3% 3.0%
Other current non-financial liabilities 1,89.1 1,489.4 1,620.1 1,479.4 1,607.1 1,385.4 1,517.8 1,561.8 3.7% 3.1% 3.2% 3.1% 3.2% 2.8% 3.0% 3.0%
Liabilities included in disposal groups classified as held for sale 0.0 0.0 0.0 0.0 0.0 96.7 156.8 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.
Total liabilities and stockholders' equity 48,637.0 48,781.9 49,906.2 48,495.4 49,504.4 49,875.0 50,141.9 51,566.6 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
2023 2024 Shares of Totals Shares of Totals 31.mar 30.czel 30.wrz 31.mar 30.czel 31.mar 30.czel 30.wrz 31.mar 31.mar 30.wrz 31.mar
31.mar 30.cze 30.wrz 31. Dez 31.mar 30.cze 30.wrz 31. Dez 31.mar 30.cze 30.wrz 31. mar 30.cze 31. mar 30.cze 30.wrz 31. mar 30.cze 3
Net financial debt 8,991.9 9,354.9 8,426.5 7,500.0 7,497.9 7,949.6 7,552.9 7,155.1 18.5% 19.2% 16.9% 15.5% 15.1% 15.9% 15.1% 13.9%
Additions to Property, plant and equipment (excl. Leasing) 297.9 669.6 1,108.0 1,775.2 305.3 695.0 1,122.7 1,734.9 n.m. n.m. n.m. n.m. n.m. n.m. n.m. n.

¹ Figures are year-to-date figures from January 1st until stated end date.